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1. INTRODUCTION
Medical devices inserted into the human body have revolutionized medicine and improved the 
quality of life or even make it possible. However, implants are prone to microorganisms seeding 
and are related with increased risk of infection.1, 2 Despite the progress in the surgical 
technique, implant design and biocompatibility, laminar air flow in the operating rooms, the 
number of medical device-associated infection raises.3 These infections represent the one of 
the most challenging complications and account for about 60-70% of healthcare-related 
infections.1, 2
Infections of the biological tissue are efficiently cleared by the immune system of the host, in 
contrast to implant biofilm infection, representing the locus minoris resistentiae for infections.2 
It is an immune depression niche causing acute or chronic inflammation and granulation of the 
tissue leading to biofilm infection.4 Therefore there are less bacteria needed to trigger an 
infection when there is a foreign body present in a host than when no implant is present.5 
According to the FDA, more than 500,000 different types of implantable medical devices are 
currently on the market. About one million cardiovascular devices are implanted worldwide,6 
and more than a million hip and knee arthroplasties are performed alone in the USA.7  
Joint prosthesis remains in the body for years to decades and infections can be classified in 
three types early postoperative, delayed postoperative, and late hematogenous infection. In 
the first 3 months after surgery can occur the early postoperative infection, the second between 
the third and 24th month from the operation, the late infections occur after 24 months and are 
related with the hematogenous implant colonization of microorganisms.2, 3, 8 The early stage 
infection is mostly induced by Staphylococcus aureus, the low-grade infection (delayed) is 
mainly caused by coagulase-negative staphylococci or Cutibacterium species (C. acnes, 
formerly Propionibacterium acnes).8 A similar infection classification applies to the fracture 
fixation devices, early within first 2 weeks after internal fixation devices, delayed between 2 
and 10 weeks, and late after more than 10 weeks from the internal fixation.8 Staphylococci are 
microorganism which are the most frequent cause of infection.8, 9  
Systemic antibiotics used to treat implant-associated infections do not always reach the site of 
infection at sufficient concentration or may cause adverse effects.10, 11, 12 Thus, there is a critical 
need for efficient and modular spatiotemporal delivery of local antibiotics in order to better treat 
biofilm infections.13  
An approach using biorthogonal chemistry to turn antibiotics into prodrugs will be presented in 
this PhD thesis. The prodrug antibiotics, which can be concentrated through click chemistry at 
an implanted biomaterial14 and released through a cascade reaction at the infected implant 
site, was investigated. Two approaches, which are based on tetrazine-modified alginate 
hydrogel and a coating of the titanium material with tetrazine-modified, mussel-inspired 
dendritic polymers (MI-dPG) using prodrugs vancomycin and daptomycin, are presented this 
thesis. Both concepts are inspired by the biorthogonal chemistry approaches, which have been 
developed until now for delivery of prodrug for cancer therapies.15 Therefore a concept of 
biorthogonal chemistry which found an application for prodrug activation to achieve local in 
vivo delivery of active medicaments will be described in the theoretical section. In addition, the 
existing antimicrobial coating achievements will be described.  
In the second part of the thesis two alternative strategies for biofilm-infection will be introduced. 
The first one will focus on the yeast prosthetic joint and bone infections. Yeast infections are 
still difficult to treat and not much research is conducted in this area. Secondly, an alternative 





The aggregation of microorganisms enclosed within the extracellular polysaccharide matrix 
(EPS) is called biofilm.16 In this 3D structure microorganisms enter into a stationary-growth 
modus.17, 18 The microorganisms within the biofilm are more resistant to antimicrobials. 19 
The bacterial cells within the biofilm form a stable community and communicate between each 
other producing and detecting signal molecules using for that a regulatory system called 
quorum sensing. In gram-negative bacteria, a acylhomoserine lactone and autoinducer-2 (AI-
2) quorum sensing system was described, whereas in gram-positive bacteria an autoinducing
peptide (AIP) system was discovered.16 For example, in staphylococci an accessory gene
regulator (Agr) quorum sensing system was extensively investigated.20, 21 Quorum sensing has
been mostly found for bacteria communication way, however, it has been also found in the
biofilms of Candida species.22, 23 C. albicans produces farnesol which has been described as
quorum sensing molecules together with other molecules including tryptophol, morphogenic
autoregulatory substance, and phenylethyl alcohol.24
2.2 Biofilm development 
The biofilm has three phases of development, attachment, maturation, and detachment.25 
Firstly, the planktonic bacteria anchor to a biotic or abiotic surface or to the host matrix protein 
called also conditioning film. The attachment to biotic and abiotic surface involves different 
interaction forces like Lifshitz–van der Waals, Lewis acid–base, and electrostatic forces.26, 27 
The electrostatic and hydrophobic interactions are present in the anchoring process to the 
abiotic surface like indwelling medical devices or polymeric surfaces. However, adhesins play 
also an crucial role in the bacteria attachment to the surface and development of biofilm. The 
adhesins are glycosylphosphatidylinositol-cell wall proteins.28 The protein adhesins are not the 
only one molecule mediating the attachment, the bacterial filamentous cell appendages also 
can behave as adhesins and expand the bacterial adhesion to the abiotic surface.29 Another 
attachment system is through collagens and fibronectins, which are the constituents of the 
ECM.30 In addition, staphylococci produce autolysins, which after proteolytic cleavage produce 
proteins amidase and glucosaminidase.31 Amidase mediates the attachment to the host matrix 
proteins, which are available on the implant surface.2 
In the case of staphylococci, autolysin or teichoic acid proteins participate in this process.32 
The complex structure of staphylococcal cell matrix network is formed by interacting of teichoic 
acids with electrostatic interactions and by the extracellular DNA, deriving from the lysed 
bacteria.33 The cell lysis is a consequence of genes controlling bacterial programmed cell 
death.20, 34 The adhesins are also present in C. albicans biofilm. They are called agglutinin-like 
sequence family adhesins (Als), whereas Als3 plays a key role in biofilm generation.35 Als can 
also be found in C. parapsilosis, however, their role in this species is not well studied.28 The 
other crucial adhesins in the C. albicans biofilm formation are hyphal wall proteins (Hwp), which 
are a constituent of germ tubes and hyphal cells.28, 36 The epithelial adhesion adhesins are the 
adhesion proteins in C. glabrata species.28 
The biofilm matrix of Candida differs from the Staphylococci one. The Candida albicans biofilm 
structure is a mixture of densely packed yeast cells within extracellular matrix, lipids, 
polysaccharides, blastophores, germ tubes, and/or young hyphae.28, 37 In contrast, the biofilm 
of Candida glabrata is formed by a multilayer packed or cluster of yeast cells and an 
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extracellular matrix with carbohydrates and proteins without hyphae.28, 38 In other Candida 
species, C. parapsilosis biofilm matrix components are yeast cells surrounded with a minimal 
extracellular matrix with carbohydrates and low level of proteins and pseudo hyphae.28, 38, 39 
Once microorganisms are attached, the maturation process starts, bacteria agglomerate, and 
the extracellular matrix forms. The EPS, which provides the three-dimensional structure for the 
biofilm, consists of polysaccharides, like hetero or homo polysaccharides, extracellular DNA, 
and proteins. Maturation of the biofilm is connected with adhesive and disruptive factors.20 The 
disruptive factors determine the formation of the characteristic channels within the biofilm.32 
The channels provide the nutrients to the bacterial cells placed deep in the three-dimensional 
biofilm matrix.20 The disruptive process has been linked to the quorum sensing system.20, 21 In 
staphylococci, Agr expression drives the biofilm detachment and regrowth by downregulating 
the surface-anchoring proteins and upregulating the expression of degradative proteases.20, 40 
The disruptive factors are involved in the final step of biofilm development and expansion. The 
planktonic bacteria are disrupted from the matrix structure and float on to form further biofilm 
and expand within entire body in vivo, possibly leading to a development of systemic 
dissemination. The detachment may be driven by enzymatic degradation as well as by 
surfactants.20, 25 It has been shown that the Staphylococcus aureus produce peptides of 
surfactant similar properties. These phenol-soluble modulins ?????????????????????-helical 
peptides.41 
Whether the host cells or bacteria occupy the medical device surface is defined as a “race to 
the surface.” It is crucial that the first calorizators will be host cells. 42 Once the bacteria are 
seeded on the implant surface, no more prevention from biofilm formation is possible by host 
cells.43 The importance of the host cells’ first colonization also lead to better osseointegration 
of the orthopedic implants where bone tissue is growing in the implant and thus integrate the 
implant in the body.44 
2.3 Implant biofilm-associated infections 
Each implant, a foreign body induces the reaction of the host immune defense system. Once 
the inflammation response is active, the neutrophils’ capacity to reduce the bacteria cells is 
dramatically altered.45, 46, 47 Moreover, bacteria can defend themselves from the host immune 
system and has an adverse influence on immune response by production of the toxins.2 
The bacteria cells are protected within the biofilm matrix. It was first believed that human 
leukocytes could not penetrate the dense mature biofilm and thus led to biofilm eradication 
difficulties.48 However, it has been shown that indeed the leucocytes can penetrate the biofilm 
structure49, the phagocytic cells could not deliver protection from the bacteria.50 The biofilms 
have the ability to change the inflammatory phenotype from pro into anti-inflammatory, which 
is related to the production of anti-inflammatory mediators.51, 52, 53, 54 The interleukin-12 (IL-12), 
which has cytokines, secreted proteins, and signal molecules, boosts the myeloid suppressor 
cells. These cells supply the anti-inflammatory biofilm surrounding by their immunosuppressive 
activity, which leads to the phagocyte influx and biofilm reduction or removal.55  
S. aureus and Staphylococcus epidermitis (S. epidermitis) are found in around 90% cases of
material associated infections. Another pathogen that plays a key role is Candida spp. For
example, C. albicans forms a polymicrobial biofilm together with S. aureus, both of which
create a barrier that reduces the sensitivity of the antimicrobial agent.56
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2.4 Diagnosis of the implant-associated infections 
Diagnosis of implant-associated infections is crucial for effective treatment.57 The traditional 
culture methods using peri-implant tissue or synovial fluid have limited sensitivity for biofilm 
detection. The sonication of the removed implant is the most sensitive diagnostic method when 
the implant is removed.58 Other authors focused on histology and evaluation of biomarkers, 
?????????-defensin od D-lactate in synovial fluid.59 Novel approaches include next generation 
sequencing technologies.60 However, new diagnostic techniques are not used in the routine 
microbiological laboratories.61, 62  
2.5 Treatment procedures for selected implants (where S. aureus is involved) 
2.5.1 Prosthetic joint associated infections (PJI) 
The infection symptoms vary depending on the time in which the infection manifests itself. In 
the first, early stage of infection, which can occur in the first 2 months after surgical procedure, 
the infections symptoms are erythema, wound secretion, or synovitis. The delayed or later 
stage of infection no longer presents these symptoms and is much harder to diagnose. The 
infection may be suspected when the patient complains of permanent pain after surgery or 
shows signs of loosening of the implant.63 Often this symptom is accompanied by a skin 
infection or pneumonia, which is not immediately associated with the symptoms of later 
infection, as well as arthritis, is a point for careful observation.57 The cytology and arthroscopic 
synovial biopsy are methods to detect infection of total knee arthroplasty. The granulocyte 
fraction higher than 65% and/or leucocytes greater than 1700/ul represent an excellent 
infection detection factor with the sensitivity of more than 90%.64 However, in late or delayed 
type of infections and in previous antibiotic therapies, the sensitivity of synovial fluid culture is 
limited. The method that helps detect infection in such cases is sonication of the infected 
implant parts.57, 65 
Prosthetic joint infections occurring early after the surgery can be treated with tissue 
debridement and implant retention. This procedure has to be very carefully performed. It should 
only be followed for specific patients where the symptoms of infection are no longer than 3 
weeks old, the implant is stable, there is no abscess, and the treated microorganism must be 
susceptible to the antibiotic used.57 To the antibiotics used in to the PJI treatment belong 
antibiotics with antibiofilms and non-growing bacteria efficacy, i.e., fluoroquinolones. In the PJI, 
the bacteria are in the stationary phase and their burden is moderate 106 CFU/ml.56 
However, delayed and late infections involve special treatment: one- or two-stage exchange 
arthroplasty. Two-stage or staged exchange arthroplasty consists of several surgeries, but 
remains a gold-standard in treatment of PJI.66 First, there is a debridement of all the dead 
tissue, and all foreign body materials are removed. The procedure is supported with several 
weeks’ intravenous antimicrobial therapy.57 The infected prosthesis is replaced by a bone 
cement spacer impregnated with antimicrobial agents, which are released from the spacer. In 
uncomplicated cases treating pathogens, the time of spacer application lasts from 2 to 4 
weeks. In this way, the joint is immobilized and the spacer is removed in a follow-up surgery 
after a few weeks and a new prosthetic joint is inserted in its place.67 In more complicated 
treatment of infections, an interval of 8 weeks is required with a bone cement spacer. This is 
so-called two-exchange revision arthroplasty with a long interval. The two-stage procedure is 
commonly used for patients with PJI, because it has a very high success rate > 90%, but is 
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associated with significantly higher costs for hospital and a patient, which is connected with 
two admissions, patient longer hospital stay, and a period of restricted patient mobility.57, 66 
One-stage or so-called direct exchange procedure, used in intact or narrowly infected soft 
tissues. In this procedure, the replacement of the infected implant with new prosthesis is 
carried out in the same surgical operation.68 There is no antimicrobial dosage used before 
operation, it is applied after the tissue samples and fluids are collected.66 The success rate in 
this operation is high, when the procedure is properly done and the treated pathogens are not 
methicillin resistant S. aureus (MRSA), fungi, enterococci, quinolone-resistant P. aerugionsa, 
or small-colony variants staphylococci57 One-stage procedure can be also used after previous 
two-stage exchange failure or by risk of relapsing.69 This procedure has its advantages 
because ex- and reimplantation of the prosthesis performed in one surgical procedure allows 
one to reduce the costs of PJI treatment, which have already been recently proven in a 
retrospective study on total hip arthroplasty PJI.66, 70 The two-stage procedure turned out to be 
related with higher complication rate comparing to one-stage exchange, however, the 
difference was not significant.71 One-stage revision does not belong to gold-standard treatment 
in PJI but there are already institutions which choose this procedure over two-stage-
exchanges, i.e., ENDO Klinik in Hamburg.72 In recent years, it has been shown that this 
procedure has gained in international popularity and acceptance by appropriate usage and 
following strict inclusion criteria.66 The absolute requirement needed in this procedure is the 
preoperative diagnosis of the pathogen causing the PJI.66 
Another procedure is only for patients who are at great risk of reinfection, such as immuno-
suppressed patients, or patients knowing that the insertion of a new prosthesis will be 
associated with an implant failure. In these patients, the infected implant is removed without 
inserting a new one. This procedure is called permanent removal. In case a patient is not 
suitable for a new operation with a new prosthetic joint, further treatment may consist of the 
long-term antimicrobial therapy, although often the infection returns after withdrawal of the 
antibiotics.57  
In order to provide the patient with a long-lasting, pain-free joint, an appropriate therapy 
consisting of a surgical procedure and well-chosen antimicrobial therapy is required. The 
treatment of implant-associated infection with antimicrobial therapy alone usually fails.57 Early 
diagnosis is crucial as curing early infection is much straightforward than treating late or 
delayed infection. In addition, it is very important not to use antibiotics empirically until the 
diagnosis is made.57 
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2.5.2 Cardiovascular devices 
A) Pacemaker and cardioverter-defibrillators (ICD)
The implantation of cardiac pacemakers and ICD is steadily increasing due to the older 
population age.73 There are two classes of pacemaker’s infections: (a) pacemaker generator 
pocket infection and (b) electrodes’ infection including pacemaker infective endocarditis where 
the pathogen has also spread along the electrodes.56, 74  
The early infection, which occurs within first 1 to 2 months after the implantation of the device, 
is called exogenous and show following symptoms: erythema, swelling, pain, erosion, warmth, 
and sinus tract. These are characteristic symptoms of pocket inflammation. However, the 
exogenous infection may manifest later symptoms when the battery pockets are infected. 
Hematogenous infection mostly lacks typical symptoms. It impacts the electrode and may be 
triggered by the bacteremia.57 
Study shows that most common pacemaker infection-causing microorganisms are coagulase-
negative staphylococci (CNS), S. aureus, and Enterobacteriaceae. S. aureus is predominant 
in the early stages of pacemaker endocarditis infections that occur in the first month after 
implantation. In the infections manifested at a later stage, the dominant organisms are CNS.56, 
75
The suggested treatment regarding pacemakers and ICD includes removal of all infected 
materials and surrounding parts, implantation of a new device under bacteremia control 
followed by antimicrobial therapy.56 The exception can be made in case of generator pocket 
infection without coexisting bacteremia, when late exogenous infection occurs. Here the 
therapy includes the generator replacement without explanation of electrodes, which is related 
with an increased risk of infection recurrence. In case of electrode infections, the exchange of 
all hardware is used.56, 57 
B) Prosthetic valve endocarditis
Prosthetic valve endocarditis (PVE) is rare but belongs to serious complications for a patient.76 
It is associated with devastating complications, i.e., ischemic stroke, increased operative 
morbidity, and mortality risk.76 The highest risk of valve endocarditis occurs in the first 12 
months after cardiac surgery and this infection is classified as early infection.77 However, the 
most PVE death cases occur in the first 3 weeks from cardiac surgery.76, 78 If the PVE is 
developed within the first 12 months from the devise implantation, it is categorized as 
healthcare-associated infection.79 
After 12 months the risk of PVE is reduced, although it remains present lifelong. The infection 
manifestation after 12 months from device implantation is called late infection56, 76, 80 In the 
case of infections immediately following cardiac surgery, we are dealing with organisms that 
come from the human skin of the patient or surgeons, therefore dominant pathogens are S. 
aureus and CNS about 50% of the time.56, 81 They are also present in the late stage of 
infections, but streptococci, enterococci, and HACEK (group of bacteria Haemophilus, 
Aggregatibacter, Cardiobacterium, Eikenella, Kingella) microorganisms predominate.77, 82 
These pathogens settle on the valve through the blood, most often through the urinary tract or 
gastrointestinal tract.56 The risk of bacteremia is mostly related with the patients with central 
venous catheters76, 83 or urinary catheters.84 Murray et al. suggested that PVE risk is increased 
by S. aureus bacteremia.85 Another risk for PVE is candidemia, which is rare and covers about 
5 to 10% of cases, but the risk of death from such infection is very high.86 Therefore the patients 
6
with prosthetic valves and candidemia must undergo an aggressively antifungal treatment 
together with long-term follow up.76 Hemodialysis has also been categorized to elevated risk 
of PVE development, especially to the S. aureus endocarditis.87 There are two categories of 
valves: mechanical and bioprosthetic. The first one shows an increased risk of PVE in the first 
three months.76, 88 The reason why mechanical risk of PVE is higher is unknown. Mechanical 
valve infection is associated with the formation of peri/paravalvular abscesses, valve 
delamination, and aneurysms resulting from the connection of sewing ring and annulus. In the 
case of bioprosthetic valves, the infection develops on the leaflets and does not cause the 
same effect as in the case of mechanical valve infection, but it leads to vegetation, cusp 
fracture, and perforation.89 
The first PVE treatment procedure consists of antimicrobial therapy. The antibiotics used for 
the endocarditis treatment are the ones with the bactericidal efficacy against planktonic 
pathogens used for at least 6 weeks or in some cases longer. Beta lactams and 
aminoglycosides belong to the bactericidal drugs. It has been suggested that the reason for 
choosing drugs with planktonic efficacy is related to the bacteria burden that reach 108-1010 
CFU/ml in endocarditis and therefore is classified as very high. Additionally, the bacteria are 
in the log phase of growth. The antimicrobial therapy may be supported with the replacement 
surgery of infected valves.56 The indication for surgery is only suggested in certain cases such 
as valve dysfunction, left-sided infectious endocarditis caused by S. aureus or fungi, 
perivalvular abscess, bacteremia, or endocarditis relapse.56, 76  
C) Vascular graft infections
Vascular graft (e.g., femoropopliteal, aortic) infections are rare but when they do occur they 
are life-threatening90 for patients with aortic grafts (up to 75%).57 They also carry a high risk of 
morbidity, in the case of vascular grafts of lower extremities valves, up to 70% of the limbs are 
amputated.56, 57
The symptoms of the vascular infections can be non-specific. The possible signs are fever, 
wound-healing difficulties, erythema, or swelling. However, low-grade fever can be the only 
signs associated with the infection. The infection related to erosion between anastomosis 
prosthesis connected with intestines show symptoms of gastrointestinal bleeding.91 The 
predominant microorganisms in these infections are S. aureus, group B-streptococci, and S. 
epidermidis.92 
The treatment must start with the microbiological diagnosis, which consists of fluid puncture 
and blood cultures that were taken prior to antibiotic therapy.57 The CT scan is a gold standard 
in the diagnosis of acute infections. For chronic infections, positron emission tomography 
shows good sensitivity and specificity.93 
In the treatment of vascular prosthesis infections, it is important to control sepsis, remove the 
infected graft, and replace with a new one, at the same time allowing the vascular supply of 
the affected organ. The broad-spectrum antibiotic therapy must immediately follow after 
surgery, and when the microbiological results are known de-escalation therapy must be 
administered with the addition of at least one antibiotic that has anti-adherent properties. 57, 93 
In specific cases, e.g., aortic prosthesis infection, an extra anatomical bypass may be used. 
This procedure involves the expertise from cardio surgeons and infection diseases specialists. 
56, 57
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2.5.3 Neurosurgical devices 
Within the neurosurgical implants commonly used are neurostimulators for the management 
of Parkinson’s disease or diseases related to movement disorders, titanium fixation devices 
for craniotomy or cranioplasty, external ventricular drainage (EVD) and lumbar drainages 
(ELD) and shunts.94  
The shunts are used in the patients with hydrocephalus conditions that increase the pressure 
in the brain by the accumulation of the cerebrospinal (CSF) fluid in the ventricles. 94 In the 
ventriculo-peritoneal (VP), the CSF fluid drains out into abdomen or peritoneum, into the 
spaces surrounding lung. The CSF fluid is drained into right heart atrium in the ventriculo-atrial 
shunts and the CSF fluid is absorbed by blood stream.95  
The diagnosis and treatment of neurosurgical devices are not trivial, as the literature about 
management of these types of infections is scarce and no guidelines are reported for these 
types of infections. The treatment procedures are often extrapolated from the management of 
orthopedic-device-infection treatment guidelines. The infections are related to high morbidity, 
mortality, and costs. The treatment costs of neurosurgical implant-associated infection are 
estimated to be higher than prosthetic joint implant-associated infections.94 The costs for 
prosthetic joint implant infections are three times higher than primary implantation.96, 97, 98  
Neurosurgical implant injection can occur at different times. They are classified as early, 
including acute, and later developing, i.e., delayed and late. The first ones develop in the first 
4 weeks after the implant placement. Acute infections are most commonly present in the 
hospital and are characterized by fever, swelling, erythema, and warmth and symptoms of 
local inflammation. In the case of these infections, the biofilm is not yet well developed and the 
therapy can therefore only consist of debridement and a subsequent 12-week antimicrobial 
therapy.94 Delayed infections are those developing during the first 12 months after implantation 
and infections occurring after a year after implant placement are classified as late.94 
The risk to develop the neurosurgical implant infection is mostly related to the skin colonized 
with bacteria or to mucosal flora.94 The infection can occur in three stages, through a skin or 
open wound preoperatively, intraoperatively through an implant that has been infected with 
pathogens, and postoperatively associated with wounds and their insufficient healing or 
wounds resulting from the placement of a drainage system.99, 100, 101 Rarely there is a 
bloodstream infection, although this may occur in shunts. VA shunts are located endovascular 
and therefore in the event of bacteremia it is also possible to develop biofilm-related infection 
on the shunt.63 For post-craniotomy infection the most frequent risk of infection origin is the 
use of preoperative chemotherapy or if CSF leakage occurs postoperatively, infecting the open 
wound, using steroids all the time, longer than usual surgery.102, 103 In shunt infections, the risk 
of infection development is first of all the earlier infected shunt, CSF leakage postoperatively, 
the application of a neuroendoscope, similar to the post-craniotomy infection prolonged 
surgery but the experience of neurosurgeons also plays an important role.104, 105, 106 The 
infection risk factors for EVD are intraventricular hemorrhage, cranial fracture with CSF 
leakage, but the catheterization time is also very important and prolonged hospital stay.107, 108,
109
There is a general recommendation for treatment of permanent implants, which includes a 
surgery to remove necrotic tissue and reduce the bacteria amount followed by the application 
of bactericidal antimicrobial agents.63, 110 In order to reduce the bacteria load in acute infections, 
it is better to clean the implant mechanically unless the injection symptoms persist for more 
than four weeks, then the implant replacement is recommended.94  
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There are two ways of proceeding with neurosurgical implant infection treatment: the first when 
the pathogen is susceptible to antibiofilm agents, the second when the microorganism is not 
susceptible to antibiofilm therapy. In the first case, the therapy consists of implant debridement 
and leaving the implant in case of early infection, or one or two-stage implant exchange in case 
of later infections. In each case, the treatment is combined with the use of antibiofilm agents 
for 12 weeks. If the microorganism is not susceptible to antibiofilm therapy, a complete removal 
of the implant with the antibiotic therapy is applied for about 6 weeks. The new insertion of the 
implant only performed after the infection has been removed. In cases of shunt infection and/or 
S. aureus, the time can be shortened to 2 weeks without the implant. The final treatment, which
is possible when the implant cannot be removed, can be considered suppressive antibiotic
therapy. The suggested intravenous treatment antimicrobial agents for infection caused by S.
aureus and MRSA include vancomycin or daptomycin in combination with rifampicin. Higher
doses are required for infection connected with the central nervous system.94
A) Infections related to post-craniotomy and cranioplasty
An operation with removal of a part of skull is called craniotomy. This surgery is performed to 
access the intracranial brain compartment. After completing the operation, the cut part of the 
skull is then returned to its position and secured with titanium plates or screws.94 Symptoms of 
this infection appear most frequently in the first days after surgery and the prevalent pathogen 
causing this infection is S. aureus and coagulase-negative staphylococci and some gram-
negative bacteria.111, 112 The most common signs of this infection are changes in mental status, 
fever, and headaches.  
In the case of craniectomy, the skull bone cut out does not return to its place immediately, here 
the patient can live without brain protection even for several months, which can affect CSF 
dynamic and cause hydrocephalus.113 Either cryopreserved autologous bone flap or a 
synthetic implant that is made of titanium, polymethyl methacrylate, or polyether ether ketone 
is used to close the skull. Here, too, the most infectious microorganisms are S. aureus and 
coagulase-negative staphylococci.113, 114  
The standard treatment procedure in both cases is to remove the bone flap or synthetic implant 
using an antibiotic therapy that can last for weeks or months. Only then is cranioplasty 
performed. There are also new suggested therapies. In case of acute infection, debridement 
and retention of the bone flap should be performed. A two-stage implant exchange with a short 
interval of no implant is also a consideration. Both of these procedures demand an antibiofilm 
therapeutic agent for the following 12 weeks after the surgery.94 
B) Ventriculoatrialand ventriculo-peritoneal shunt infection
VP shunts are most commonly used as they are related to less complication rate. The 
Ventriculoatrial (VA) shunts are related to more complications as: cardiac arrythmia, 
myocardial injury, intra-cardiac thrombi, or endocarditis.115, 116 VAs are only chosen for the 
patients who have had abdominal surgery or who have had earlier complications with VP 
shunt.94 The most common infectious pathogen in early shunt infection are microorganisms 
found on the skin flora, i.e., S. aureus, coagulase-negative staphylococci, and C. acnes, in 
later infections they are often polymicrobial.101 There are no clear symptoms immediately 
indicative of shunt infections. The signal that may indicate an infection is that the shunt will 
stop working and it will be recognized by the repeated hydrocephalus, which can cause a 
headache or vomiting. Further symptoms are ventriculitis and meningitis. In VP shunt infection 
additional symptoms are peritonitis or intraabdominal pseudocysts. In VA shunt infections 
typical symptoms are right-sided endocarditis and fever.101, 117, 118  
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There is no gold standard for treatment of shunt infections. There are, however, suggested 
ways to proceed. After diagnostics based on valve punction and SCF sample collection and 
blood culture, the appropriate steps are taken. If there is no meningitis, abscess, shunt 
dysfunction, or skin erosion, the infected implant can be retained and antibiofilm antibiotics are 
given for 12 weeks. If any of these is present, the infected implant must be replaced 
immediately. The replacement consists of removal of the implant and antibiotic therapy. When 
the infection is cured, a new implant can be inserted. In the case of S. aureus and a negative 
blood culture, a new implant can be inserted after 14 days. If a new implant is inserted, CSF 
culture is negative, a 4-week antibiofilm therapy following reimplantation is suggested.94 
2.5.4 Mammary implants 
The infection rate of mammary breast implants is estimated on 2% for patients with simple 
augmentation96 and higher about 12% for patient with previous breast cancer and mastectomy 
followed by immediate implant placement.119 The predominant pathogens are S. aureus, 
Enterobacteriaceae, and P. aeruginosa.57 Swelling, pain, difficult and chronic wound healing 
accompanied by fever are common symptoms of mammary implant early acute infection.  
The standard therapy include similarly to periprosthetic joint infection removal of the infected 
implant, followed by delayed replacement of an implant and long-lasting antimicrobial agents 
therapy.120 However, therapy with direct implant substitution, immediate new implant insertion 
prior for pocket curettage, debridement, and postoperative antimicrobial application is also 
considered to be successful.120, 121 
2.6 Preventive strategies for implant-associated infections 
It has been shown that the care bundle approach used by a patient before the surgery gives 
the maximum outcome benefit. The care bundles include whole-body decolonization with 
proper antiseptic agents.122 It has been found that one risk factor for prosthetic joint infections 
(PJI) is the preoperative anemia. The risk to develop the infection is doubly increased in this 
case.123, 124
2.6.1 Implant-based preventive strategy 
The implant surface is so important that changing its characteristics has a huge impact on the 
adhesion of microorganisms and thus on the development of biofilm. Different coatings offer 
surface superhydrophilicity, antifouling, and bacteria repelling surfaces.125, 126, 127, 128 Ideally 
prosthetic joint implants should also boost tissue integration by a fast host cell implant 
colonization.129, 130
Many of the coating technologies are already advanced and tested in the clinical studies, which 
mostly includes materials with coating that release antimicrobial agents and repel bacteria.2 
Material that is supposed to be protected by bacterial colonization should have repelling or 
killing properties. It is suggested that this can be achieved by modifying the surface of the 
material without damaging the bulk properties of the implant. Chouirfa et al. suggests dividing 
surface modification methods into surface modifications or coatings of the material surface. 
Both can be sub-divided into physical and chemical or a combination of the two.131 
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A) Surface modifications
Modification of the implant surface aims to introduce antibacterial properties on the implant 
surface by immobilizing small molecules. The molecules can be inserted into the implant 
surface in two ways, through adsorption, which does not necessarily provide a suitable stable 
coating131, and through covalent bonding of the molecule to the surface.132 Covalent, strong 
bonding can be divided into those that require a suitable anchor, the so-called "grafting to" 
coatings, and those that require a polymerization on the implant surface, the "grafting from" 
coatings.131 
A.1 Grafting “from”
It has been reported a process that introduces a polymer on the surface of a titanium implant 
in several steps. First, the oxidation of the titanium surface was applied through sulfuric acid 
and hydrogen peroxide, which generates titanium hydroxide or peroxide on the surface of the 
implant. In the next step, by heating or UV irradiation, radicals were formed on the surface, 
which were used to connect to a highly concentrated styrene sulfonate monomer.133, 134 This 
method showed an effective inhibition of S. aureus by comparing it to an implant without 
coating.133, 135, 136 However, the “grafting from” methods are composed of multiple coating steps 
and need no special water and oxygen conditions and therefore have turned out to be more 
complicated then “grafting to” methods.137 
A.2 Grafting “to”
A coating, which binds the molecule to the implant surface, uses different anchors, i.e., 
silane, catechol, and phosphor.  
Figure 1. Titanium surface functionalization with different anchors to prepare an antimicrobial surface. Modified 
reprint with permission from reference131. Copyright, 2019, Acta Biomaterialia. 
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A.3. Silane anchor
Silanization has been used to introduce peptides, polymers, or proteins into the titanium 
surface. The hydroxyl groups present on the titanium surface are further modified using 
alkoxysilane.131 Chen et al.138 used (3-aminopropyl)triethoxysilane to introduce amino groups 
on the titanium surface, then they used bifunctional linker ester to introduce the melimine on 
the surface. It is a synthetic peptide, which shows a wide spectrum of antibacterial and 
antifungal activity. This coating showed a significant in vitro reduction in adhesion of S. aureus 
and P. aerugionsa biofilm by comparison to the titanium without coating. In the in vivo case, 
where substrates were tested with a mouse and rat infection model, that coating showed a 
reduction in bacterial count of 2 log10.138 A further example of the silane anchor use is the 
coating introduced by Gerits et al.139, where the antimicrobial agent SPI031 was covalently 
bonded to titanium using (3-aminopropyl)triethoxysilane. This coating also demonstrated in 
vitro and in vivo reduction in S. aureus and P. aeruginosa biofilm formation. 
A.4 Catechol anchor
Catechol can be used in a variety of ways as an anchor. The first option is to functionalize a 
polymer with catechol. Such a polymer can then be easily attached to the titanium surface.140 
There have been three adsorption modes according to the density function theory.141 
Depending on the pH value used for the reaction, there are different types of bindings: in lower 
pH bidentate hydrogen bonding between protonated catechol hydroxyl groups and interfacial 
oxygen on the titanium surface, one monodentate H-bonds combined with a single 
coordination bond at intermediate pH, and at elevated pH values fully deprotonated catechol 
coordinates with interfacial oxygen on the titanium surface to form bidentate two coordination 
bonds.142  
Figure 2. pH dependent binding modes of DOPA to titanium surface. Modified reprint with permission from 
reference131. Copyright, 2019, Acta Biomaterialia. 
Another alternative is to first introduce the catechol on the titanium surface and then to connect 
it to a functionalized polymer by means of a reaction click.143 The catechol can also be 
introduced by an initiator with catechol group in direct polymerization.131 Hu et al. showed in 
vitro a reduction of S. aureus adhesion to titanium where carboxymethylchitosan (CMCS) and 
hyaluronic acid-catechol (HAC) were grafted to the surface through a dopamine anchor. The 
bacteria amount was reduced to 16% for a CMCS dopamine coating and 54% with HAC 
coating compared to uncoated materials.144  
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A.5 Phosphor anchor
Phosphates and phosphonates can functionalize the titanium surface by covalent binding into 
it and they can be connected to the desired molecule that is supposed to be attached to the 
surface. These types of linkers are more stable in physiological pH than silane linkers, which 
demonstrate instability in aqueous solutions.131 
It has been shown that phosphate functionalized molecules can be directly bounded to the 
TiO2 layer without a crosslinking agent.145 The titanium surface with such attached molecule 
was incubated with Strep. sanguinis and showed a decrease in adhesion of this bacteria.  
Pfaffenroth et al.146 investigated the antimicrobial activity against Streptococcus mutans of the 
titanium surface which they previously functionalized with copolymers of 4-vinyl-N-
hexylpyridinium bromide and dimethyl-[2-(methacryloyloxy)ethyl] phosphonate. The polymers 
formed an ultrathin layer on the titanium surface with antimicrobial properties.  
B) Coating of the surface
B.1 Physical
Chouirfa suggested two sub-categories of a physical coating, bacteriostatic and bactericidal.131
a) Bacteriostatic coatings
These coatings show an electrostatic repelling bacteria activity without a bacterial killing effect. 
Bacteriostatic surfaces can be introduced by using hydrophobic modification of the TiO2 layer 
or by polyethylene glycol (PEG) hydrogel or any other molecule forming similar gels.131  
Polycations and polysaccharides coatings 
It has been shown that a titanium coating based on PEG, poly(L—Lysine), and an antimicrobial 
peptide RGD compared to S. aureus and S. epidermidis showed a reduction of 98% and 93-
95% bacteria, respectively.147 Chua et al. showed that the longer the polysaccharide chain, the 
more Lifshitz-Van der Waals forces are reduced on the surface and the S. aureus adhesion 
decreases. A reduction of 80% has been reported.148 A coating based on chitosan and alginate 
was introduced onto the titanium surface by the layer-by-layer self-assembly technique. The 
coating was first loaded with minocycline, a broad-spectrum antibiotic. After the release of the 
drug, the antimicrobial properties of the coating could be biostatically maintained by its surface 
charge and hydrophilic properties.149 However, the mechanical stability of the gel coatings is 
still a concern. It is recommended by application of the materials with such coating to avoid 
screwing, this however, can be hardly avoided in implant surgery.131 
Smart polymers coatings 
Polymers, which respond to numerous stimuli like temperature, pH, and light, etc., are called 
smart polymers.150 Poly(N-isopropylacrylamide) is most widely used polymer in this group, 
because it responds to temperature changes, is used to control the wettability properties of a 
surface, and displays a lower critical solubility temperature (LCST) in water at 32°C. It shows 
hydrophilic properties below LCST temperature, at the temperatures above LCST, it is 
hydrophobic, is no longer water soluble, and changes its length presenting a collapsed 
structure.131 Lee et al.151 proved that a titanium surface coated with 
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poly(N-isopropylacrylamide) could detach S. aureus and Porphyromonas gingivalis by 
decreasing the temperature below LCST.  
b) Bactericidal coatings
These coatings aim to kill bacteria by interfering with the bacterial membrane.
Polycations 
Polycations may be used to disrupt the bacterial outer and cytoplasmic membrane because 
they are attracted to the negatively charged proteins and teichoic acid in the gram-positive 
bacteria and to negatively charged phospholipids in the gram-negative bacteria. Schaer et al. 
proved the antibiofilm properties of the hydrophobic polycation N,N-dodecyl,methyl-
polyethylenimine and studied this coating with S. aureus.152  
Coating with antimicrobial peptides 
Antimicrobial peptide been developed as an alternative for the antibiotics. Rodriguez Lopez 
?????????????????????????-amino acid-based peptidomimetic of antimicrobial peptide from the 
chitosan hyaluronic acid coating.153 ???? ?????????? ??????? ????? ???? ?-peptide displayed 
excellent properties for mammalian cells attachment and provided long-term release of the 
antimicrobial peptide, which showed its antimicrobial activity against S. aureus. Other research 
groups incorporated the antimicrobial peptide Tet213 into the calcium phosphate and coated 
it on the titanium surface.154 The authors claimed the very fast in vitro killing of S. aureus and 
P. aeruginosa within first 30 minutes.
Coating-releasing ions 
Chlorine, iodine, copper, calcium, and some other chemical elements have been used to 
incorporate themselves into titanium or hydroxyapatite coatings. The anodic oxidation of the 
ion is used to introduce them into the coating. By hydroxylation, the ions can be turned into 
highly reactive molecules like HCl, hydrogen peroxide, or superoxide (O2-), which results in cell 
permeability and finally in cell death with oxidation.131 Iodine coating is the only ion-based 
coating that found an clinical application.155 It also went successfully through a single Level 2 
random-controlled study and gained much interest in Japan.156  
Coatings using photoactivity of the titanium surface 
Titanium oxide is a photoactive semiconductor, which can be used for the bacteria elimination 
under the application of ultraviolet A light in the wavelengths between 315 and 380 nm.131 The 
photoactivation of titanium surface work in two steps, first the photo-activated TiO2 surface 
removes the hydrocarbons by oxidation and provides super-hydrophilic surface. A second step 
is necessary to produce reactive oxygen species which then, by oxidation, the cell membrane 
leads to cell death and therefore introduces antimicrobial properties on titanium surface.157 
This method is limited to the light access to the implant. Therefore, not all implant-associated 
infections can be treated using this method.  
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Coatings with nanoparticles 
There are several metal-based nanoparticles used for microbial eradication. These are copper, 
silver, gold, zinc, and magnesium nanoparticles, which range from 1 to 100 nm.158 However, 
the antimicrobial properties of nanoparticles are under discussion as some research groups 
did not find any antibacterial activity of those molecules159, 160, whereas the other authors 
reported significant (more than 90%) bacterial burden reduction.161 The authors who used 
nanoparticles together with organic or inorganic antimicrobials showed reduced bacterial 
attachment to the surface.159, 162, 163 Similarly, excellent biocidal properties against S. aureus 
and E. Coli have been shown with silver nanoparticles.164, 165 
Coating incorporating antimicrobials 
Coating incorporating the antimicrobials can be prepared in different ways. The most common 
way is to soak the coating in the antimicrobial solution or impregnate the coating with 
antimicrobial drugs.131 The advantage of local antimicrobials application is that they do not 
cause systemic toxicity. However, the systemic application of antibiotic, as a support for the 
local therapy, is suggested for peri-implantitis treatment protocol.166 By choosing the drug for 
the coating, the coating conditions have to be considered. If the coating involves high 
temperatures, a temperature-stable antibiotic has to be chosen.131 Metsemakers et al. reported 
a successful application of the gentamicin-coated tibia nails Expert Tibia Nail (ETN) PROtect 
in the human clinical study for 16 patients.167 The coating is composed from poly(D,L-lactide) 
matrix containing gentamicin sulfate and is fully resorbable. The coating is introduced to the 
surface by the dip coating procedure and showed a burst release of 70% within the first 24 h 
from the implantation.168 Other antibiotics, which are integrated in the release coating, are 
vancomycin, tetracycline, amoxicillin, and cephalothin. They all represent activity against 
bacterial surface colonization.169, 170 
Silver coatings 
Silver has been broadly used in the antimicrobials coatings as it represents wide spectrum 
antibacterial susceptibility and, at the same time, displays antibacterial activity also against 
polymicrobial infections.171 In its ionic form, Ag+ eradicates bacteria in different modes of action, 
by inhibiting inter-membrane transport, blocking cell duplication, or disrupting the cells.56 Silver 
is supposed to bind to DNA and thiol groups in the protein and thus disrupts cell membranes 
and proteins.172 Silver is the most commonly used metal for the antimicrobial coatings showing 
good antimicrobial properties with hydroxyapatite coatings171, 173, silver-loaded gelatin 
microspheres on the porous titanium structure.174 A discussion has been raised about the silver 
toxicity in the human body. Therefore its use has been restricted in the patients with high post-
operative risk factor.131 
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B.2 Chemical
a) Chemical vapor deposition (CVD)
CVD, which is a reaction with gaseous reactants, found a broad application in the industry. It 
provides high quantity and quality coatings with a well-controlled coating process.131 Its 
application as a convenient coating against pathogens has not been widely used, but there are 
some evidences showing its usage in the antibacterial coating against E. coli. The graphitic 
C3N4 has been introduced onto the titanium nanotube layers through one-step CVD. Then 
using visible light source it demonstrated strong photocatalytic antimicrobial activity.174  
b) Sol-gel coating
Sol-gel is a technique, which has found many applications in coatings of various applications. 
This method creates a colloidal solution on the surface of the material. The colloidal solution 
can be an inorganic material into which organic polymers or nanomaterials can be 
introduced.175 This method is extremely comfortable and easy to use and ultimately results in 
the formation of a gel on the surface of the coated material.131 
Antibiotics can also be introduced this method within the gel on the surface of the material and 
thus create an antimicrobial coating. As it was done by Radin and Ducheye176 who introduced 
vancomycin onto the surface of titanium material. Another antimicrobial coating was shown by 
Gollwitzer et al.177 who introduced copper (II) acetate monohydrate to the TiO2 surface using a 
sol-gel technology. Thus, coated materials were subjected to testing against S. aureus and 
exhibited reduced adhesive strength of this bacteria to the material surface. 
c) Nitride coatings
Titanium nitride found its application in metals used in clinics and dentistry. It is a material that 
provides the surface with high corrosion resistance, it strengthens the surface structure of the 
material, it is chemically inert, and it has a low friction coefficient. It has also been successfully 
tested for its biocompatibility.131 Its antimicrobial properties remain disputable. Some of authors 
have indicated the lack of bacterial adhesion effect178, 179 while others assessed its activity on 
Strep. mutants and demonstrated bacterial adhesion reduction.180  
2.7 New approach for biofilm-based infections 
There is not much research conducted using bioorthogonal chemistry to tackle biofilm-based 
infections.  
Bioorthogonal reactions or click reactions, includes chemical reactions which occur in the 
biological milieu being at the same time inert to the biochemical processes.  There are different 
type of biorthogonal chemistries, among others, Staudinger ligation, stain promoted azide-
alkyne cycloadditions (SPAAC), copper(I)-catalyzed azide alkyne cycloaddition (CuAAC), 
inverse-electron demand Diels-Alder (IEDDA) reaction.181 Bioorthogonal chemistry has found 
a promising application for prodrug activation to achieve local in vivo delivery of active 
medicaments.15 For those Staudinger and inverse-electron demand Diels-Alder (IEDDA) 
reactions have been the most widely used. 
Turning the drug into a prodrug has the benefits that undesirable drug properties such as 
systemic toxicity can be temporarily switched off via a temporary mask of the functional group 
which is the reason for undesirable properties. Additionally, the potency of the drug can be 
improved by tethered to a vector molecule such as antibodies, which leads to targeted delivery. 
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The ideal prodrug is stable while circulation in a human body and cleavable only at the desired 
location. There are two types of prodrug modification, one which lead to the release based on 
chemical reaction and second where the release of an active drug is driven by the enzymatic 
reaction.182 Examples of enzyme triggered reaction include, among others, hydrolysis, which 
causes release of an active substance from an ester prodrug.182 Prodrug, which contains 
disulfide linkers will be triggered by reducing agents.183, 184 The most common enzyme-
activated prodrugs are those that contain linkers susceptible to, inter alia, esterases, proteases 
and phosphatases.185 
There are different bioorthongal triggers for release and thus activation of products, these are 
among others182: 
2.7.1 Reaction using azido group as a latent amino group 
The azido group is used to activate a prodrug by nucleophilic addition or self-immolative 
elimination. Here, the classic Staudinger reaction was modified in order to include 
intramolecular cyclization and it is been called Staudinger ligation. In this reaction a prodrug 
(Drug=R1NH2) is activated by azido containing compound. A Staudinger ligation followed by 
self-immolation has found an application in cancer therapies.186 Robillard et al. reported 
doxorubicin (doxo) prodrug activation via the Staudinger reaction.187 The doxo-prodrug 1 
(Figure 3) used in his study includes azido group. This group was converted into amino group 
by phosphine compound 3. The intermediate undergoes self-immolation through 1,6-
elimination which leads to activation of doxorubicin and release of byproduct 11. At 37°C in 
aquatic conditions the reaction between 1 and 2 was completed within 20h.  
Figure 3. Staudinger reaction for the activation of the prodrug. Reprint with permission from reference182. Copyright 
2019 Royal Chemical Society. 
Guo et al. showed that conjugation of antibody and a fluorophore with a cleavable linker with 
azido group can be used to label the protein of interest.188 After a treatment with a phosphine 
compound the intermediate released a fluorophore.  
These reactions proofed that reduction of azido group can be used for the activation of a 
prodrug. However, the reducing agent - phosphine used for this purpose can be easily oxidized 
in cell culture medium at 37°C. The fast oxidation was observed within the 4h. This issue limits 
the usage of phosphine to trigger the prodrug activation in vivo, as the control of its 
concentration is barely possible. Other drawback of this reaction is its reaction rate constant 
k2 = ~10-3 M-1 s-1 189 This means that to provide a reasonable half-life a high concentration of 
these two reactants has to be delivered.  
Bertozzi et al. introduced a modification of Staudinger ligation, a Staundinger-Bertozzi 
ligation190 Figure 3 where the reagent 1 and 2 reacted through click reaction forming amide 4 
and releasing the 5.  
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Figure 4. Staudinger ligation-based bond-cleavage reaction. Reprint with permission from reference182. Copyright 
2019 Royal Chemical Society. 
Gamble et al. introduced a new strategy to activate an azido group with trans-cyclooctene 
(TCO) without the usage of phosphine.191 The highly reactive TCO activated the azido prodrug 
(Figure 5) through the 1,3-dipolar cycloaddition and forms 1,2,3-triazoline, followed by nitrogen 
release and formation of aldimine, hydrolysis and 1,6-elimination.  
Figure 5. Azido prodrug. Reprint with permission from reference182. Copyright 2019 Royal Chemical Society. 
The click reaction between TCO and azido compound is categorized by Sustmann’s group192 
as type-II 1,3-dipole cycloaddition in which an electron withdrawing group attached to the 
phenyl ring of azido prodrug (Figure 5) should decrease the LUMO energy level and thus the 
higher reaction rate could be achieved. It has been shown that k2 increased from 0.017 M-1 s-
1  to 0.110 M-1 s-1 when using fluoro-substitution.182 However, the introduction of fluoro group 
caused a slowdown in decaging of the intermediate compounds.193 This type of reaction, 
compared to Staudinger reactions improved the activation of azido group by increasing the 
reaction rate and enhancing the stability of the activated compounds.182  
2.7.2 Reaction between tetrazine and benzonorbornadiene 
The cycloaddition reaction between tetrazine and benzonorbornadiene was introduced in 
2017.194 This reaction (Figure 6) is combined with the elimination of nitrogen and the formation 
of intermediate 3, which in retro-Diels-Alder cycloreversion leads to the production of self-
immolative isobenzofuran/isoindole intermediate, followed by CO2 elimination and release of 
an active payload. The reaction rate constant between 1b and 2a-c was 0.190 ± 0.029 M-1 s-1 
in water. This second order rate constant was higher than present in Staudinger ligations k2= 
~ 0,001 M-1 s-1 and TCO and azido compounds k2= 0.137 M-1 s-1.182 
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Figure 6. Cargos release from benzonorbornadiene derivatives due to tetrazine. Modified reprint with permission 
from reference182. Copyright 2019 Royal Chemical Society. 
The reaction between 1b and 2d was studied for cancer treatment drug delivery.182 This 
reaction showed very fast release of a doxorubicin within 360min in a mixture of DMSO/PBS 
(1:1) at 37°C. No toxicity at 20μM was observed for the prodrug doxorubicin 2b and the stability 
in DMSO/PBS was noted for 48h.  
2.7.3 Tetrazine/alkene reaction 
The inverse-electron demand Diels-Alder (IEDDA) reaction between tetrazine and trans-
cyclooctene (TCO) was found to be applicable for in vivo bioconjugation. This reaction yields 
stability in vivo but also is inert to other biological functionalities.15 Due to the very fast rate 
constant (k2> 103 M-1 s-1)195, 196, the reaction between trans-cylcootene and s-tetrazines has 
gain much interest for use in the nuclear medicine where the reaction rate and short-half lives 
are of priority consideration.196 This reaction can undergo in aqueous conditions and thus fast 
due to the acceleration by the hydrophobic effect.195 Several research groups have shown the 
application of TCO-conjugated antibodies and their reactions to tetrazine-payload to combat 
cancer cells.197, 198 The reaction between tetrazine and trans-alkene has been shown to be 
very fast click reaction with a reaction rate which can be easily modified by using different 
functional groups attached to these compounds.199, 200, 201 There has been a lot of research 
done to use these two reagents to deliver drugs by using "click and release" reaction.202 This 
reaction, reported in 2013 by Robillard et al., showed that the intermediate 1,4-
dihydropyridazine 3 formed after cycloaddition between TCO and tetrazine.203 This can 
undergo two reactions: direct elimination or first tautomerization, which is then followed by a 
1,4-elimination and ends up with the release of compound 6 and a payload compound R1NH2. 
This reaction has been employed for the doxorubicin delivery. Doxorubicin was modified with 
TCO. The resulting prodrug, which was incubated with 2b and 2c at 37 °C, led to very fast 
release within 4 and 6 minutes, respectively. It showed 55% release for 2b and 79% release 
for 2c. There was no release observed when prodrug was incubated alone in PBS or in serum, 
which proved the stability of the drug and the release drive explicitly by tetrazine.182 The fastest 
reaction of all tetrazines was reported between 1a and 2a, however, with a low doxorubicin 
release (only 7%). The low amount release was explained by the intermediate 4 and 5, which 
did not undergo further reactions. The doxorubicin-prodrug turned to be about 100 times less 
toxic than a doxorubicin alone. 
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Figure 7. Inverse-electron-demand Diels-Alder reaction between trans-cyclooctene and tetrazine. Modified reprint 
with permission from reference182. Copyright 2019 Royal Chemical Society. 
Chen et al. conducted a study with different substituents on the tetrazine ring.204 The electron 
withdrawing group (EWG) attached to the tetrazine improved the cycloaddition reaction 
constant rate and significantly and reduced the decaging rate. The introduction of electron 
donating group caused exactly the opposite effect for decaging reaction and did not improve 
the release yield. In order to achieve a balance between the cycloaddition reaction and the 
decaging rate, it was found that the use of these two groups was optimal for this purpose. 
Weissleder et al. showed that the high release between 2c and 1 turned to be an artifact driven 
by the acidic conditions in HPLC.204 When this reaction performed in PBS at pH=7 the release 
yield after 6h of incubation was around 20%. It was thus proven that the payload release 
improved in an acidic environment. In response to this, they began to synthesize tetrazine with 
carboxylic acid groups. The addition of carboxylic group protonates the dihydropyridazine 
nitrogen which leads to enhanced tautomerization to dihydropyridazine followed by 1,4-
elimination (Figure 8B). The introduction of two carboxylic groups on the tetrazine 2f (Figure 
8A) showed almost complete release in PBS at pH=7, only trace elements of dead-end product 
for 2e-g was observed. The low release yield of 2c was related to the formation of a dead-end 
product (Figure 8C). The dead-end product coming from the intramolecular nucleophilic 
addition of the amidic nitrogen has no further possibility to decage the payload. To avoid the 
intramolecular cyclization which leads to the dead-end product formation a methyl group (3c) 
was introduced on the amidic nitrogen. This structure incubated in PBS with tetrazine 2c 
achieved a complete release.  
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Figure 8. Dihydropyridazine intermediate (un)release mechanisms. (A) different tetrazine derivatives, (B) 
Intramolecular acid assisted elimination proposed mechanisms (C) The dead-end product formation. Modified 
reprint with permission from reference182. Copyright 2019 Royal Chemical Society. 
Royzen et al. used this chemistry to image-guided prodrug activation.205 For that iron oxide 
nanoparticles (MNPs) modified with tetrazine fluorescent dye were used. The doxorubicin was 
modified with TCO into a prodrug 1a (Figure 7). The dye was used for MNPs tracking in vitro 
and in vivo. The specific localization of the nanoparticles in MDA-MB-231 breast cancer cells 
was confirmed. The presence of the MNPs in the tumor cells efficiently converted the 
doxorubicin prodrug into an active drug. which helps the dosing of the prodrug 1a. Next, the 
same group have introduced a new concept of biorthogonal chemistry to concentrate and 
activate drug at the desired location.15 In order to simply the tetrazine delivery to the targeted 
site and at the same time protect it from the washed out from the desired place, the alginate 
hydrogels were modified with tetrazine (HMT). Thus, the release of a TCO-prodrug at the 
location of choice (e.g. tumor) depends on the presence of the HMT. Royzen et al. 
demonstrated in vivo, in mice bearing fibrosarcoma a significant therapeutic benefit of prodrug 
doxorubicin released from HMT injected in the proximity of soft tissue sarcoma. The tumor was 
observed and after 2 weeks from the last therapy in both group TCO-doxorubicin and 
doxorubicin the tumor was not detectable in both groups. However, after 30 days the tumor 
size in the group treated with doxorubicin regrowth and was measured to have the volume of 
2000 mm3, whereas the median tumor size for TCO-doxorubicin group remained furthermore 
not detectable.  
2.8 Non-antibiotic-based strategy to elimination of biofilm-based infections 
Photodynamic therapy (PDT) has found an application in the antimicrobial treatment due to 
the increasing number of antibiotic resistances. The microorganism killing effect of the 
photosensitizers (PS) is based on the generation of reactive oxygen species that eradicate 
pathogens by an oxidative burst.206   
A light source activates the PS. There are 3 light sources for the PDT: lasers, light-emitting 
diodes (LEDs), and gas-discharge lamps.207, 208 In recent years, intensive research has been 
carried out for new PS and energy sources.206 Many different PS have been used and include 
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phenothiazinium derivatives, such as toluidine blue, which have shown inhibitory properties for 
S. aureus.209 Porphyrin, chlorine, and phthalocyanine derivatives have also been applied. The
chlorine e6 can eliminate bacterial infection of S. aureus and E. coli and has excellent
biocompatibility.210 Curcumin, which is a component of the curcuma longa rhizome, is used to
treat inflammation and has been found as well to have antimicrobials and antioxidants.211, 212
Most of these compounds are first used to deactivate planktonic bacteria. The most common
method used is the screening method of many compounds to later select PS, which are
suitable for further chemical modification in order to improve their antimicrobial efficacy.213
2.9 Polymethyl methacrylate (PMMA) bone cement commonly used in the clinic to 
combat biofilm-based infections 
The acrylic bone cement which are impregnated with antibiotics have been widely applied in 
the clinic for the treatment of musculoskeletal infections.214 The cements are used in two forms: 
beads impregnated with antibiotics or spacers.215 Spacers loaded with antibiotics have found 
the application in the knee and hip arthroplasty.216, 217 The choice of antibiotics used in the 
PMMA cement bones have to be carefully made. There are many criteria antibiotic has to fulfil 
in order to qualify as a good candidate for the incorporation into PMMA. Among others: the 
thermal stability of the antibiotic is a key property as the polymerization of the PMMA is related 
to production of high temperatures. Moreover, antibiotic has to be available in a powder form 
and ideally has a broad antibacterial spectrum. Additionally, the amount of the antibiotic and 
its release properties from the cements are crucial for the success of the therapy. For the 
eradication of methicillin sensitive or resistant infections PMMA spacers with gentamicin and 
vancomycin are recommended.214 
If the pathogen of the periprosthetic joint is known, the PMMA cements can be used as a 
specific treatment of that pathogen. They can also be applied for the prophylaxis, where the 
pathogen is not known and the antimicrobial treatment is then considered as non-specific. 
There are already industrial preparations of PMMA bone cements premixed with antibiotics. 
The antibiotic however can also be mixed preoperatively with the bone cement.218 
The PMMA bone cement can be used for a treatment of hip and knee arthroplasty infections. 
In this case they are used to improve the antibiotic delivery, stabilize the skeleton. They are 
used in the period between removal of an infected implant and insertion a new implant. The 
antibiotic spacers stays at the place of previously removed infected implant and by delivering 
the antibiotic in the surrounding tissue heal the infection.218  
The antibiotic-based PMMA bone cements are commonly use in the clinic, however little is 
known about fungal-impregnated PMMA bone cements and there is no such cement available 
on the market with the industrial premixed antifungals. There is also little known about fungal 
PJI treatment.219 Candida PJI are rare but they but they are a very big threat to the patient's 
life.220 Therefore more investigation and research is needed in this direction. 
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3. SCIENTIFIC GOALS
3.1 Bio-Orthogonal chemistry-based reloadable biomaterial to enhance the treatments 
against Staphylococcus aureus infections 
The theoretical part indicates that in the implant-associated infections there is no optimal 
strategy yet to protect the implant from bacterial colonization for the entire time the implant is 
located in the human body. The most common strategy in the implant infections treatment, and 
so far, the only one recognized worldwide, is to remove the infected implant, followed by 
antimicrobials administered intravenously which can be facilitated with combination of local 
antibiotics release from bone cements.  
The first big aspect is the lack of a method that would facilitate the antibiotic local delivery 
which can lead to the eradication of maturated biofilm without removing the infected implant.  
Therefore, the main objective of this PhD work is to address the first aspect, which will be 
based on the development of a method that can facilitate the eradication of biofilms without 
removing infected implants and the development of a coating that can be loaded with 
antimicrobials after placing the implant in the human body.  
Following the successful drug delivery approaches in the biorthogonal chemistry and keeping 
in mind how different substituents influence the click and release reaction, in this PhD thesis 
the inverse-electron demand Diels-Alder (IEDDA) reaction was used to develop a new strategy 
for combating biofilm associated infections and the results are reported at ACS Central 
Science.202 The technology presented in this PhD thesis utilizes an implantable biomaterial 
(tetrazine-modified alginate hydrogel) and prodrugs formed by conjugating trans-cyclooctene 
(TCO) groups to antibiotics. Using the inverse electron demand Diels-Alder reaction between 
tetrazine and TCO the antibiotic’s therapeutic index can be increased and allows a higher 
quantity of the antimicrobial to reach the bacterial infection site (Figure 9). 
Two FDA-approved antibiotics were used: vancomycin and daptomycin. Both antibiotics are 
used in the treatment of S. aureus infections, including MRSA. Vancomycin as a "last resort" 
antibiotic is used in exceptional situations, including the elimination of planktonic bacteria that 
surround the infected implant.221 It is used to combat gram-positive bacteria and the mode of 
action is very well known. This tricyclic glycopeptide inhibits the synthesis of bacterial cell 
wall221, 222 However, the use of vancomycin is limited because of the side effects associated 
with its use, such as tachycardia, nephrotoxicity and hypotension.223 The second antibiotic, 
cyclic lipopeptide daptomycin has a narrow therapeutic window: 6 mg/kg to control S. aureus 
bloodstream infections.224 The mode of action of this antibiotic is not as well-known as 
vancomycin, although it is known that calcium ions are needed for the antibiotic to have an 
impact on bacteria in order to oligomerize for permeabilization and cell membrane 
depolarization of the bacteria.225 Daptomycin is also used to control S. aureus biofilm 
infections, thus it is good to use it against implanted associated infections.226 However, 
daptomycin have shown side effects related to the use of high concentrations227 and limited 
biodistribution.228 Therefore, in this PhD thesis these two antibiotics were selected to increase 
their activities against S. aureus infections. Both antibiotics were modified to prodrugs with 
TCO and their release from hydrogel modified with tetrazine (HMT) and activity against MRSA 
and methicillin-sensitive S. aureus (MSSA) were investigated in vitro and in vivo.  
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Figure 9. The click-chemistry strategy for concentration and activation of pro-drug antibiotic which are inceted 
systemically. (A) implantation of the Tz modified alginate gel (TAG) at the infection site. (B) Intravenous infection a 
pro-drug antibiotic (C) when the prodrug and the TAG come in contact, the IEDDA reaction enhances the amount 
of antibiotic present near the infected site. (D) Spontaneous isomerization of the cycloaddition product, following by 
the CO2 release and an active antibiotic. Reprint with permission from reference202. Copyright 2018 American 
Chemical Society. 
3.2 Mussel-inspired polyglycerol combined with bio-orthogonal chemistry - as a 
coating strategy for implant associated infections 
The antimicrobial coating strategy has been a subject of extensive research. However, these 
type of coatings have some limitations. The pathogen that is being fought against must be well 
diagnosed before implant with antibiotic coating can be inserted into the patient's body. Once 
the antibiotic is released, implant remains without protection from bacteria. Coating based on 
release of ions, nanoparticles often have tissue toxicity problems and cannot be applied to all 
patients.   
Therefore, the second aspect that has been addressed in this PhD thesis utilizes the same 
bio-orthogonal chemistry as for biomaterials described above. This chemistry was used for the 
titanium coating where the loading of antibiotics can be done after the implant insertion into 









C. Concentration of the prodrug
on the implant
D. Activation and release of the
antimicrobial and on the
implant
Figure 10. IEDDA-based titanium antimicrobial coating that concentrates, activates and releases intravenously infected 
prodrug antimicrobial. (A) The tetrazine-coated prosthesis is implanted in the infected area, (B) prodrug  injected systemically, 
(C) prodrug covalently reacts with the coated implant, (D) The spontaneous isomerization and the release of active drug. TCO:
trans-cyclooctene.
A tetrazine-based coating was developed. The coating for the titanium surface composes of 
mussel inspired polyglycerol dendritic polymer (MI-dPG) modified with tetrazine. MI-dPG 
mimics the properties and composition of the mussel foot proteins.140 The mussels attach very 
quickly to any type of surface under water using mussel foot proteins (mfp-1 and mfp-5)-rich 
byssus.229 Both proteins contribute to surface adhesion due to lysines and 3,4-
dihydroxyphenyl-l-alanine (DOPA) which interact with the surface through covalent or 
noncovalent bonds.230, 231 The amino groups in lysines crosslink each other or coordinatively 
crosslink with Fe3+ ions, which leads to byssus solidification.232 MI-dPG is a heteromultivalent 
catechol- and amine-functionalized dendritic polymer which mimic the mfp-1 and mfp-5 in their 
functional groups, structure and molecular weight.140 The MI-dPG has a similar molecular 
weight to the mfp-5, about 10 kDa.233 Due to high molecular weight as well as multivalent 
functional groups this polymer can form within minutes strong and stable coating.140 The 
dopamine and its derivatives adhere to different type of surfaces, without a necessity of surface 
modification.234, 235 The coating is driven by covalent and coordinative crosslinking.236 It is a 
universal coating for virtually any type of surface. The catechols within the polymer were used 
in this work for covalent attachment to the titanium surface, amino groups used for covalent 
attachment of tetrazine to the coating with the goal of spatiotemporal delivery of the antibiotics 
to the coated surface. In this project the release of the prodrug daptomycin from the tetrazine-
MI-dPG coating was tested, the activity of the released drug against MRSA was investigated,
stability of the coating and biocompatibility and cytotoxicity against mouse myoblasts and
human osteoblasts was examined.
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3.3 PMMA bone cements with antifungals 
Another aspect are the currently used PMMA bone cement spacers for treatment of bone and 
implant-associated infections. The PMMA commonly include only antibiotics, there are no 
commercially available bone cements with antifungals. 
In this project different antifungal amphotericin B (AmB) formulations were evaluated in regard 
to PMMA bone cement incorporation. There are two available AmB formulations: non-
liposomal sodium-deoxycholate and liposomal AmB. They were compared with a new 
formulation: non-liposomal N-methyl-D-glucamine/palmitate AmB. The reason for testing the 
new antifungal formulation was that the AmB deoxycholate is hardly water soluble and has a 
limited usage due to toxicity. Liposomal formulation due to its large amount of liposomal 
powder might negatively influence the mechanical properties of PMMA bone cements. The 
antifungals were incorporated in the PMMA bone cements by mixing the methyl methacrylate 
powder and monomer liquid (N,N-Dimethyl-p-toluidin) and letting the materials polymerize at 
room temperature. Thus, the PMMA formed cylinders have been studied for several aspects: 
whether there is a release of the antifungal from the material, whether the released drug is 
active against Candida biofilm, how the introduction of the antifungal into PMMA affects the 
compressive strength, density and porosity of the PMMA material, whether the new AmB 
formula might be an alternative candidate for PMMA incorporation, additionally an addition of 
poragen was studied.  
3.4 Photodynamic-based strategy for bacterial eradication 
Finally, from the theoretical part, it is clear that the treatment currently used is mainly based 
on antibiotics. Inadequate application of antibiotics might increase the risk of resistance 
development. Therefore, in this project, a photosensitizer curcumin was chosen as an 
antimicrobial agent. As a material for curcumin incorporation a hydrogel was chosen. The 
hydrogel is a recognized material for wound dressing and can maintain a moist environment 
at the healing site. Such a highly hydrated environment can accelerate the development of 
pathogens and also facilitate their attachment on biomaterials. Therefore, in this project, hybrid 
hydrogel-containing graphene oxide was used which was loaded with an antimicrobial 
compound. This hydrogel has electro-responsive properties that offer highly tunable drug 
releasing conditions. A curcumin, which is a natural ingredient of Curcuma longa and a 
photosensitizer used in antimicrobial photodynamic therapy, was chosen as an antimicrobial 
agent.  We applied electrical stimulations with a range of 0 to 48 V voltage and examined the 
response of the hydrogel. We also investigated the kinetic characterization and evaluated the 
curcumin release and its activity against methicillin-resistant S. aureus. Additionally, we tested 
the response and viability of human fibroblast cells. 
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In the following section, the scientific outcomes of this PhD thesis are listed, and the 
contributions of the authors are specified. 
4.1 Bio-Orthogonal Chemistry and Reloadable Biomaterial Enable Local Activation 
of Antibiotic Prodrugs and Enhance Treatments against Staphylococcus aureus  
Infections.  
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4.2 Titanium coating by combining concepts from bio-orthogonal chemistry and 
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Abstract 
Implant-associated infections present serious complications for patients. The implant surfaces 
colonized by bacteria lead to prolonged hospitalization due to patient immobilization and extended 
antibiotic treatments that sometimes lead to liver or kidney toxicity. In this work, we describe the 
inverse-electron-demand Diels-Alder reaction and hydrolytic release between mussel-inspired, 
dendritic tetrazine-coated titanium prosthetic materials and trans-cyclooctene modified daptomycin 
used against methicillin resistant Staphylococcus aureus. Characterization of the materials’ properties 
revealed that it is hydrophobic, non-toxic, and stable for prolonged periods of time. The coating is 
functionalized with tetrazine and is capable of transforming a prodrug of daptomycin to the active 
drug. We envision that this material will be able to improve the treatment of implant-associated 
infections by concentrating systemically administered antibiotic prodrugs, and increasing the local 
concentration of active drug, thus converting the prodrugs into localized medicines. 
1. Introduction
The orthopedic implant-associated infections (OIAI) cause devastating post-surgical complications.[1] 
Despite of enormous progress of modern medicine and the use of laminar-flow systems in operating 
rooms, surgical site infections cannot be prevented completely in today’s hospitals.[2] About 5% to 10% 
of all inserted internal fixation devices cause implant-associated infections. The incidence may even 
exceed 30% after fixation of grade 3 open fractures.[3] Despite considerable progress in prevention and 
treatment of OIAI, the absolute number of patients with such infections continues to rise due to the 
lifelong risk of bacterial seeding on the implant and aged patients requiring joint replacement.[4] 
OIAI originates from the free-floating bacteria that colonize the titanium surface of surgical 
implants and over time evolve as a biofilm infection. As the result, treatment of OIAI is extremely 
difficult as biofilm embedded bacteria are more resistant to conventional antibiotics than their 
planktonic counterparts.[2,5,6] Staphylococcus aureus is one of the most common OIAI pathogens[3,7] and 
methicillin-resistant Staphylococcus aureus (MRSA) is of particular concern.[8] OIAI treatment with 
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conventional systemically injected antibiotics is not sufficient as they not reach their intended targets 
in large enough concentrations, but instead spread throughout the body. Due to the lack of specificity 
for the pathological site, large doses are required to achieve effective therapeutic concentrations. This 
leads to frequent dosing, systemic side effects, and toxicity and could potentially lead to the 
development of multi-drug resistance of the respective pathogen.[9,10] 
Antimicrobial coatings have been developed to overcome bacterial colonization of titanium 
surfaces. They include silver-based coatings that, due to toxicity concerns, have been limited to 
patients with high postoperative risks.[11] Also, several vancomycin-releasing materials have been 
described in recent literature.[12] Thompson et al. described a gentamicin releasing calcium-phosphate 
coating on titanium aluminum-niobium. However, all of these examples predetermine the 
antimicrobial treatment at the time of implantation. This is potentially problematic, as the treatment 
cannot be modulated or altered at the outset of OIAI. Ideally, the treatment should be determined at 
the time of an infection and the dosage adjusted based on therapeutic need. 
In this work, we describe the development and characterization of a mussel-inspired tetrazine-
functionalized surface coating, which is non-toxic, hydrophobic, and stable. The material is capable of 
activating a prodrug of daptomycin via bio-orthogonal inverse-electron demand Diels-Alder 
chemistry.[13] We describe the synthesis of the coating and detailed characterization of its properties. 
Our long-term vision is that this material will be capable of converting systemically administered 
antibiotic prodrugs into active local medicines. In the event of OIAI, the modified prodrug of 
daptomycin will be systemically injected. It would circulate through the body in its inactive prodrug 
form. Upon binding the tetrazine-functionalized prosthetic surface, the prodrug will be transformed to 
the active daptomycin, thus locally targeting the infection. In this way, an efficient and modular 
spatiotemporal delivery of therapeutics will be achieved.[14] 
2. Results and Discussion
Our group previously developed a mussel-inspired dendritic polyglycerol (MI-dPG) as versatile material 
for surface functionalization. We have previously shown that MI-dPG can attach to virtually any surface 
within a short period of time. It is a stable coating that can be further functionalized with small 
molecules or nanoparticles.[15-18] MI-dPG mimics the properties and composition of the mussel-foot 
proteins.[19] The mussels attach very quickly to any type of surface under water using mussel foot 
proteins (mfp-1 and mfp-5)-rich byssus.[20] Both proteins contribute to surface adhesion due to lysines 
and 3,4-dihydroxyphenyl-l-alanine (DOPA), which interacts with the surface through covalent or 
noncovalent bonds.[21,22] The amino groups in lysines by crosslinkage with each other or coordinative 
crosslinkage with Fe3+ ions lead to byssus solidification.[23] MI-dPG is a heteromultivalent catechol- and 
amine-functionalized dendritic polymer which mimics the mfp-1 and mfp-5 in their functional groups, 
structure and molecular weight.[19] The MI-dPG has a similar molecular weight to the mfp-5, about 10 
kDa.[24] Due to high multiplicity of functional groups, this polymer can form strong and stable 
multivalent coatings within minutes. [19] The dopamine and its derivatives adhere to different type of 
surfaces, without a necessity of surface modification.[25,26] The coating is driven by covalent and 
coordinative crosslinking.[27]  
The role of the MI-dPG is dual, while the catechol groups are important for the anchoring on 
the titanium surface; the amino groups of MI-dPG are used for attaching a bio-orthogonal group, 
tetrazine (Tz). Through this modification, the titanium surface will be converted into a functional 
material capable of activating systemically administered antibiotic prodrugs, as illustrated in Figure 1. 
The strategy is related to our recent report, describing local activation of systemically administered 
prodrugs using bio-orthogonal chemistry.[13,28] The strategy will involve the Tz-modified titanium 
surface (MI-dPG-PEG-Tz) and a daptomycin prodrug created with a modification with trans-
cyclooctene group (pro-dapto). The systemically administered pro-dapto will react with MI-dPG-PEG-
Tz and will locally activate daptomycin on the titanium surface. 
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Figure 1. IEDDA-based titanium antimicrobial coating, which concentrates, activates, and releases 
intravenously infected prodrug antimicrobial. (A) The tetrazine-coated prosthesis is implanted in the 
infected area, (B) the prodrug is injected systemically, (C) prodrug covalently reacts with the coated 
implant, and (D) the spontaneous isomerization and the release of active drug. TCO: trans-
cyclooctene. 
2.1 Synthesis of MI-dPG-PEG-Tz 
Figure 2. Coating steps for titanium coating with MI-dPG-PEG-tetrazine coating. 
MI-dPG-PEG-Tz was synthesized in three steps illustrated in Figure 2. MI-dPG was synthesized
following the procedure previously reported by our group.[19] Coating of the first layer was carried out
over 16 h, by treating each side of the titanium surface with a methanolic solution of MI-dPG and MOPS 
(pH 8.5). After subsequent washes, Fmoc-protected PEG was coupled as the second layer. The Fmoc
groups were cleaved with 20% piperidine in DMF. Lastly, tetrazine was installed using HATU as a
coupling reagent. The detailed synthetic procedures are described in the experimental section.
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2.2. Cytocompatibility  
2.2.1 Cell toxicity 
The MI-dPG-PEG-Tz titanium coating, in conjunction with pro-dapto treatment, is non-toxic to 
myoblast cells and human osteoblasts cells. This was assessed using a cell counting kit-8 (CCK-8) cell 
viability assay.  As illustrated in Figure 3, there was no significant difference in the viability of C2C12 
cells treated with titanium, MI-dPG-PEG-Tz, or MI-dPG-PEG-Tz + pro-dapto. The cell viability was 83% 
in the presence of MI-dPG-PEG-Tz and 81% in the presence of MI-dPG-Peg-Tz coating previously 
incubated with pro-dapto. As shown in Figure 4, the MI-dPG-PEG-Tz-coated material reduced the 
osteoblast cells viability by 4% relative to titanium material. Meanwhile, MI-dPG-PEG-Tz + pro-dapto 
showed a cell viability reduction of 6%. The small reduction of cell viability has been attributed to the 
excessive growth of osteoblasts on titanium surface. Cell proliferation in medium has comparable 
viability (non-treated control), 96% and 94% for the MI-dPG-PEG-Tz and MI-dPG-PEG-Tz + pro-dapto 
respectively (Figure 3). 
By contrast, some of the already developed silver coatings have been known to have toxicity. 
In fact, the broad spreading of the AgNPs coating started a debate on the toxicity of these types of 
coatings.[29] A relevant toxic effect on gall bladder and midzonal hepatocellular necrosis in mice have 
been shown using 10 nm AgNPs size coatings, independently from the type of coating. The small AgNPs 
have enhanced tissue distribution and therefore found in most of the mice organs.[29] Wentong Lu et 
al. reported a toxic effect on human HaCaT keratinocytes when the AgNPs citrate-coated powder was 
used.[30] It has also been presented that toxicity of silver acetate and polyvinylpyrrolidone-
stabilized AgNPs showed the same toxic effect against bacteria, as well human mesenchymal stem cells 
(hMSCs), and peripheral blood mononuclear cells. There were also controversial results doubting in 
the antimicrobial properties of the silver coatings that showed no significant difference between 
titanium coating with silver and uncoated materials.[11]  
Figure 3. Viability of the C2C12 mouse myoblasts cells after cultivation with CCK-8 kit. Statistical 
analysis was performed using one-way ANOVA analysis. The samples were performed in triplicates; 
the error bars represent standard error measurement. 
Figure 4. Viability of the osteoblast cells after cultivation with CCK-8 kit. The samples were performed 
in triplicates; the error bars represent standard error measurement.  
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2.2.2 Osteoblast adhesion 
A B
C D
Figure 5. SEM pictures of the materials showing the attachment of the cells to the material’s surface. 
The arrows indicate proliferated osteoblast cells. (A) Titanium without osteoblasts, (B) titanium with 
osteoblasts, (C) titanium coated with MI-dPG-PEG-Tz, and (D) titanium coated with MI-dPG-PEG-Tz and 
treated with pro-dapto for 1 h, prior to osteoblast experiment. 
The morphology of osteoblasts and the attachment of the cells to the materials were analyzed using 
scattering electron microscopy (SEM). The osteoblasts were fixed after 24 h incubation, prior to SEM 
analysis. The results confirmed that the experimental materials did not create toxic microenvironment 
that prevented healthy cell growth. Figure 5A shows SEM images of the titanium surface without 
proliferated cells. Figure 5B shows growth of osteoblast cells on the untreated titanium surface. As 
indicated by the arrow, the attached cells had a healthy cellular morphology, the cells grew equally, 
and showed elongated cell bodies. The cells attached to the MI-dPG-PEG-Tz surface, shown in the 
Figure 5C, also represented a healthy morphology. Treatment with pro-dapto also had minimal effect 
on the healthy cell growth, as shown in Figure 5D. These results were complementary to the cell 




2.3. Release kinetic results 
A B
Figure 6. Release kinetic of a prodrug (A) HPLC analysis of supernatant and (B) cumulative release. 
Activation of pro-dapto was tested in vitro by treating MI-dPG-PEG-Tz coated material with PBS 
solution of the prodrug pro-dapto. Upon incubation in PBS, the supernatant was collected and 
analyzed by HPLC. Figure 6 A illustrates the analysis of the collected supernatant solutions. Figure 6 B 
shows the cumulative release of daptomycin. Daptomycin was released shortly after treatment of MI-
dPG-PEG-Tz with pro-dapto and continue to form for up to 1 month thereafter. Based on the observed 
data, over 90% of drug release occurred within 7 days after the treatment. 
2.4 Surface characteristics 
2.4.1 Synthesis of MI-dPG-PEG-Tz-titanium coating 
In order to control the attachment of the coating to the surface, the visual observation was done as 
well as the static water contact angle was measured. Each coating step showed a change in the surface 
colors, indicating the presence of the coating on the surface. The MIdPG-coated materials turned 
yellow, whereas tetrazine addition turned the materials to a pink color. Recent studies have shown 
that implant’s hydrophilicity could enhance proliferation of osteoblasts on the implant’s surface.[31] 
SWCA measurements were performed to evaluate the surface properties of MI-dPG-PEG-Tz. The 
coating procedure consists of several steps and we used SWCA to monitor every coating step and the 
changes introduced to the material’s surface. The SWCA for the titanium surfaces exceeded the 90° 
threshold, indicating considerable hydrophobicity (Table 1). The SWCA for the titanium surface was 
determined to be 96° ± 16°. The further coating with MI-dPG reduced the SWCA to 54° ± 2°, 
transforming the material’s properties from hydrophobic to hydrophilic. Coating with Tz retained the 
hydrophilic properties with SWCA well below 90°. The SWCA increased to 63°± 5°, which is still in the 
hydrophilic regime. The hydrophilic properties of MI-dPG-PEG-Tz make it a potential candidate for 
further in vivo testing. 
Picture of the surface Material Contact angle 
Titanium 96° ± 16° 
Titanium coated with MI-dPG 54° ± 2° 
Titanium coated with MI-dPG-PEG-Tz 63° ± 5° 
Table 1. Contact angle values for different surface coating steps. The samples were measured at least in 
triplicates and the mean value plus/minus standard deviation is presented in the table. Tz: tetrazine. 
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2.5. Coating stability 
The MI-dPG-PEG-Tz coating completely covered the titanium surface. This was confirmed by the X-ray 
photoelectron spectroscopy (XPS) analysis of the titanium surface. As shown in Table 2, the coated 
samples completely lacked any Ti2p signals. Meanwhile, the C, N, and O compositions changed 
significantly after introduction of the coatings. Furthermore, we treated the surface with 1% SDS for 1 
month and reanalyzed the samples. The percentage compositions of C1s, N1s, and O1s for the coated 
sample after the one month’s incubation showed similar values for both coated samples. Highly 
resolved C1s spectra (Figure 7) showed minimal changes in C-O/C-C components’ ratio from 0.82 for 
the freshly coated material to 0.71 for the incubated material. These results suggested that the coating 
was stable for the studied period of time. 
C 1s at% N 1s at% O 1s at % Ti 2p at% 
Titanium 29,2 0,8 50,7 17,1
Titanium 1 month in 1% SDS 34,3 1,3 47,6 14,7 
Titanium coated 70,4 7,8 20,2 0,0 
Titanium coated and 
incubated 1 month in 1% SDS 
69,2 7,7 22,0 0,0 
Table 2. XPS surface analysis from the coated and uncoated materials. 
Figure 7. Highly resolved C1s spectra of (a) titanium coating with MI-dPG-PEG-Tz and (b) titanium 
coating with MI-dPG-PEG-Tz after 1 month of incubation in 1% SDS solution. 
2.6. Coating thickness 
There are several different techniques for coating thickness measurements.[32-34] In this work SEM was 
employed, as it turned out to be a straightforward and optimal method, which did not involve a 
material breakthrough to determine the coating thickness for our samples. Before MI-dPG-PEG-Tz 
coating was performed, the part of materials was covered according the procedure published by 
Griesser et al.[35] using poly (D,L,-lactide) (Figure 8). This enabled us to measure the coating thickness 
without breaking the material. The thickness was measured at three different points and the average 
of the three measurement points was used to determine the results. The results have shown the 
thickness of 49.62 ± 5.57 μm (Figure 9). 
Figure 8. The titanium material coated with MI-dPG-PEG-tetrazine with uncoated parts left after poly 
(D,L,-lactide) layer.  The arrow indicates the place where the coating thickness was measured. 
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Figure 9. MI-dPG-PEG-tetrazine-coating thickness. 
2.7 Ability of MI-dPG-PEG-Tz titanium coating to activate a prodrug of daptomycin 
Figure 10. Minimum inhibitory concentration for planktonic MRSA versus pro-dapto for samples 
where no coated material was present (w) and samples, which were previously incubated with the 
MI-dPG-PEG-tetrazine-coated material (MT).
A series of microbiological tests was performed to evaluate the ability of MI-dPG-PEG-Tz to activate a 
prodrug of daptomycin (pro-dapto). We used the standardized optical density and turbidity 
absorbance method [36] to measure the minimum inhibitory concentration of the supernatant (bacteria 
growing medium) from the pro-dapto or daptomycin incubation with MRSA. The antibiotic 
concentration that resulted in zero absorbance at OD600 was identified as the minimum inhibitory 
concentration (MIC). Bacteria incubated with the pro-dapto prodrug showed an MIC value of 12 μM 
(Figure 10). In the presence of MI-dPG-PEG-Tz, pro-dapto was converted into daptomycin, thus 
resulting in a 4-fold reduction of MIC (3 μM). In a control experiment shown in Figure S3, we tested 
the antibiotic activity of daptomycin without or without the material. The observed values were 
virtually identical, indicating that the material did not have any anti-bacterial activity of its own. 
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Figure 11. Minimum biofilm prevention concentration (MBPC) of the pro-dapto incubated either non-
coated titanium (T) or MI-dPG-PEG-tetrazine-coated materials (MT). 
The ability of MI-dPG-PEG-Tz to activate the prodrug of daptomycin was also evaluated for a biofilm-
forming bacteria. The MI-dPG-PEG-Tz was pre-incubated with pro-dapto, followed by the addition of 
MRSA inoculum. After an overnight incubation at 37 °C, the titanium materials were washed with 
saline, vortexed, and sonicated. The sonication fluid was plated on the Müller-Hinton agar plates and 
the colony forming units (CFU) were counted. The lowest antibiotic concentration, which resulted in 
zero CFU on the agar plates, was considered as minimum biofilm prevention concentration (MBPC). As 
illustrated in Figure 11, the MBPC for pro-dapto on titanium was at 24 μM. On the other hand, pro-
dapto previously incubated with MI-dPG-PEG-Tz had a 4-times lower MBPC value of 6 μM. Analogous 
experiments with daptomycin showed no difference in the MBPC values, indicating that the material 
does not have antibacterial properties of its own. In agreement with our previous published work,[28] 
the material is capable of activating antibiotic prodrugs via the bio-orthogonal IEDDA chemistry. 
Numerous antibacterial titanium approaches have been developed: in contrast to our study 
Davidson H. et al. presented covalently attached antibiotics to the titanium surface, which 
prevented the implant surface from the gram-negative bacteria colonization.[37] Shu He et al. reported 
cefotaxime sodium immobilization on the polydopamine-coated titanium surface that prevented 
the materials from the Escherichia Coli and Streptococcus mutants proliferation.[38] Min-Kyung Kang 
et al. showed similarly to our work a release of antibiotic from titanium coating.[39] They present a 
single dose release where the majority of the drug was released within the first 24 h. Once the drug 
was released, no more modification of the coating or loading with the antibiotic was possible. 
The antibiotic pre-loaded coatings required prior planning of the targeting the bacteria. If it 
turns out during the treatment another bacterium is a constituent of infection, such a coating will 
no longer perform its function. Our approach represents a coating, which might be manipulated 
after the implantation of the prosthesis. The coating is a platform that can activate and release 
virtually any TCO-modified antimicrobial.[28] 
3. Conclusions
We have described the synthesis and characterization of a mussel-inspired dendritic polyglycerol 
coating for titanium surfaces that can activate antibiotic prodrugs via a bio-orthogonal IEDDA 
reaction. Coating with MI-dPG-PEG-Tz is non-toxic to myoblast and osteoblast cells and allows healthy 
adhesion of human osteoblasts to the treated surface. XPS experiments showed that the coating 
covered the entire titanium surface and that the coating is stable for an extended period of time. 
The coating was found to be hydrophobic and uniform. Our bacterial experiments showed that MI-
dPG-PEG-Tz-coated titanium surface can activate the pro-dapto and release the free 
daptomycin. Free daptomycin released at the close proximity to the implant facilitates the 





Materials: Daptomycin (Cubicin) was purchased from Novartis Pharma (Bern, Switzerland). All other 
chemicals were purchased from Krackeler Scientific and used without further purification. 
Chromatographic purifications were conducted using SiliaSphere™ spherical silica gel 5 ????????????????
gel (Silicycle). Thin layer chromatography (TLC) was performed on SiliaPlate™ silica gel TLC plates (250 
????????????????????????????????????????????????????????????????????????????????????????????????????
??????? ????????? ??????????????????????????????????????????????? ??? ????? ??-20 Instrument using 
Phenomenex Luna 5u C18(2) semi-preparative column (250 x 10 mm) using a gradient of 10-70% 
CH3CN (0.01% formic acid) in H2O (0.01% formic acid). HATU and 2-[2-(Fmoc-amino)ethoxy]ethoxy 
acetic acid was purchased from Sigma Aldrich/Merck KGaA, Darmstadt, Germany. Analytical HPLC was 
performed on Shimadzu LC-20 Instrument using Phenomenex Luna 5u C18(2) column (250 x 5 mm). 
COSTARR Spin-????????????????????????cellulose acetate), purchased from Fisher Scientific (cat# 07-
200-385), were used for the kinetic experiments. 1H, 13C, and 2D NMR spectroscopy was performed on
a Bruker 500 and 600 MHz NMR instruments. All 13C NMR spectra were proton decoupled. LC-MS data
was acquired using Agilent Technologies 6530 Q-TOF instrument. Methyltetrazine acid was kindly
provided by Alexander Oehrl, research group of Prof. Haag. Customized Ø 6 mm x 1 mm titanium plates 
were kindly provided by Zimmer Biomet UK Ltd (Dorcan, Swindon SN3 5HY).
Daptomycin prodrug synthesis: In our previous publication we had made an initial daptomycin prodrug 
modified by TCO with limited results (TCO-Dapto). This publication presents the results of pro-dapto, 
a daptomycin prodrug modified at its most active side ornithine (Orn6) residue with characteristics 
that optimized their drug properties, e.g., stability. It has been already shown by Marahiel[40] and in 
our previous study[28] that modification at this amino acid site alters the daptomycin activity.  
MI-dPG- synthesis: According to the work of Sunder et al.,[41] the synthesis of hyperbranched
polyglycerol (dPG) was performed via the one-step, ring-opening, multi-branching polymerization
(ROMBP) of glycidol. Next, dPG-amine was synthesized by the transformation of all terminal hydroxyl
moieties to amines. This transformation was performed via (1) -OH mesylation, (2) azidation, and (3)
azide reduction, as earlier described in several works by Haag and coworkers.[42]The dPG-amine was
then transformed to MI-dPG by functionalizing 40% of the terminal amine groups with 3,4-
dihydroxyhydrocinnamic acid (DHHA), according to an earlier published procedure by Schlaich and
coworker[16]: dPG-NH2 (4 g, 3.8*10-1 mmol) was dissolved in 100 ml of MeOH, and the pH was adjusted
to 7 using an aqueous HCl-solution (10%). Next, an aqueous buffer solution of 2-(N-morpholino) ethane 
sulfonic acid (MES) (100 ml, 0.1 M, pH: 4.8) was added to the solution. Subsequently, DHHA (20 g, 110
mmol, 2 eq. according to all -NH2 moieties) and 1-ethyl-3-(3-dimethylamino)propyl)carbodiimide (EDC) 
(21 g, 110 mmol, 2 eq. according to all -NH2 moieties), were added to the solution, and the reaction
mixture was stirred at room temperature for 16 h.
Purification of the crude product was performed by dialysis in MeOH (dialysis molecular weight cutoff 
(MWCO): 2 kDa). To increase MI-dPGs’ stability in solution, i.e., to prevent oxidation and subsequent 
crosslinking, a concentrated HCl solution (37%, 12M) was added in small amounts (i.e., 1 drop per gram 
of product). After purification, the solvent was removed under reduced pressure, and the product was 
stored in the freezer (-20 °C) under inert atmosphere (Ar). 
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Figure 12. MI-dPG with the dPG backbone (black), and the OH moieties (red). 
Coating procedure: MI-dPG was dissolved in MeOH and diluted 1:1 with 3-(N-
morpholino)propanesulfonic acid MOPS pH 8.5 (final MI-dPG concentration 2 mg/ml). Coating was 
done overnight (at least 16 h), from each side of the material separately. Subsequently, the materials 
were washed three times with sterile double-distillated H20 and one time with MeOH and dried at 
room temp. The 40 mg of 2-[2-(Fmoc-amino)ethoxy]ethoxy acetic acid linker (0,104 mM, final 
concentration 1mg/ml) in DMF was added to 71 mg of HATU (0.187 mM, 1.8 equivalent) dissolved in 
DMF and finally 0.343 mM (3.3 equivalent) DIPEA was added to the mixture. Each material was 
immersed in 300 μl of the mixture and the liquid surrounded the material from each side. The 
incubation was done overnight at room temp. Next day the liquid solution was discarded and all 
materials were washed three times with DMF. The substrates were then transferred into new 2ml 
Eppendorf tubes. For the fluorenylmethyloxycarbonyl-protecting group (Fmoc) deprotection, solution 
of 20% piperidine in DMF was prepared. The materials were incubated in 300 μl of the piperidine/DMF 
solution for 30 min. at room temp on the shaker 100 rpm. After the incubation, the fluorescence of 
the supernatant was measured. In order to prove the Fmoc separation, we measured dibenzofulvene–
piperidine adduct, which is generated by the cleavage of base-labile Fmoc group, with 20% (v/v) 
piperidine in DMF at 301 nm.[43] The results are shown in Supplementary Information (Table S1). The 
dibenzofulvene–piperidine adduct was then discarded and the materials were vigorously washed using 
vortex 3x with DMF. Finally, the supernatant was discarded and the materials were washed 3 times 
with DMF, using vortexing in order to wash out the Fmoc properly.  Subsequently 40 mg of 
methyltetrazine acid was dissolved in DMF (0.19 mM, final concentration 1mg/ml, 77mg HATU in DMF 
(0.2 mM, 1.1 equivalent) was added and 0.37 nm of DIPEA was mixed together and 260 μl of the 
mixture was added to each material, which was placed in the 2 ml Eppendorf tube. Incubation was 
done overnight at room temp. The next day, the liquid solution was discarded and the materials were 
washed 3x with DMF and 1x with MeOH. 
Antibacterial analysis 
Bacterial strains and growth conditions: The microbiological experiments were carried out using 
Staphylococcus aureus methicillin resistant MRSA strain (ATCC 43300). Stocks of each strain were 
preserved on cryovials (Roth, Karlsruhe, Germany) at -80°C. The strains were cultured on a Müller-
Hinton agar (Oxoid, Hants, UK), and incubated at 37 °C for 24 h. The inoculum concentration of 2x105 
CFU/ml was prepared dilution of a 0.5 McFarland solution. The quantitative cultures were used in order 
to determine inoculum concentrations. 
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Minimum inhibitory concentration (MIC) determination- planktonic bacteria analysis: The pro-dapto 
and daptomycin dilutions were prepared in Müller-Hinton II broth (Becton, Dickinson, Le Pont-de Claix, 
France) (adjusted to final 50-55 mg calcium/L). The titanium materials with or without coating were 
incubated with 700 μl of the diluted antibiotics in order to allow the drug to attach to the coating. After 
1 h incubation, 700-μl inoculum of 2x105 CFU/ml was added. The bacteria together with the materials 
and antibiotics were incubated for 24 h at 37 °C. The day after the medium of the incubated samples 
was tested to determine the MIC by measuring the absorbance at 600 nm, using the microplate 
spectrophotometer (Epoch, BioTek). MIC was defined as the minimum concentration needed to inhibit 
the growth of MRSA, which resulted in the same absorbance as the negative control without bacteria 
(medium only).  
Titanium surface analysis- biofilm analysis: After 24 h incubation, the titanium materials were removed 
from the medium, bacteria, drug solution and washed 3 times with 0.9% NaCl to remove all planktonic 
bacteria.  Next, the materials were placed in 500μl PBS and vortexed for 30 seconds, followed by 
sonication for 60 sec. at 1 MHz, lastly vortexed again for 30 sec. and the sonication fluid was plated on 
the Müller-Hinton agar plates. The agar plates were incubated overnight at 37 °C and the colony 
forming units (CFU) were enumerated the day after.  
Cell viability: Cell viability was determined using a CCK-8 Kit (Sigma-Aldrich Chemie GmbH, Taufkirchen, 
Germany) according to the manufacturer’s instructions. C2C12 (mouse myoblasts) and hPOB 01 
(human primary osteoblasts) cells were kindly provided by Britt Wildemann, Julius Wolff Institut - 
Charité – Universitätsmedizin Berlin and cultured in DMEM (high glucose with 10% FCS, 100 U/mL 
penicillin and 100 μg/mL streptomycin, Thermo Fisher Scientific, Waltham, Massachusetts, USA) or 
DMEM/Ham´s F-12 (stable glutamine with 10% FCS, 100 U/mL penicillin, 100 μg/mL streptomycin, 50 
μM L-ascorbat-2-phosphate and 200 ??? ?-glycerolphosphate, Biochrom, Berlin, Germany), 
respectively. Prior to the experiment, the coated substrates were sterilized with aqueous EtOH (70%), 
rinsed with sterile Dulbecco's phosphate-buffered saline (DPBS without calcium and magnesium, 
Sigma-Aldrich, Taufkirchen, Germany), and dried in a cell culture hood. Next, the substrates were 
placed in a sterile 24-well plate (Sarstedt, Nümbrecht, Germany), 500 μL DMEM was added, and the 
plate was also placed in an incubator (Heraeus Holding GmbH, Hanau, Germany) at 37 °C and 5% CO2. 
For the cell viability test, cells were seeded in a 96-well plate at a density of 5 x 104 cells/mL in 
90 μl cell culture media per well overnight at 37 °C and 5% CO2. After overnight incubation, 40 μl per 
well of cell culture medium were discarded and 50 μl of medium exposed to the substrates were added 
to cells. SDS (1%; 0.1%) and non-treated cells served as a control. For background subtraction, also 
wells containing no cells but only sample were used. Cells were incubated 48 h at 37 °C and 5% CO2. 
After incubation, the CCK8 solution was added (10 μl/well) and absorbance (450 nm/650 nm) was 
measured after approximately 3 h incubation of the dye using a Tecan plate reader (Infinite pro200, 
TECAN-reader Tecan Group Ltd.) Measurements were performed in triplicates and repeated three 
times. The cell viability was calculated by setting the non-treated control to 100% and the non-cell 
control to 0% after subtracting the background signal using the Excel software. 
Osteoblast Adhesion and Fixation for Scanning Electron Microscopy: Frozen primary human osteoblast-
like cells (hpOB 02) isolated from human donors’ femoral head were kindly provided by Britt 
Wildemann, Charité (approval of the ethics committee from the Charité-Universitätsmedizin Berlin 
(EA4/035/14). For the experiment, they were thawed and cultured in Dulbecco's modified eagle 
medium (DMEM high glucose with 10% FCS, 100 U/mL penicillin and 100 μg/mL streptomycin, Thermo 
Fisher Scientific, Waltham, Massachusetts, USA) until they reached confluence. Prior to the 
experiment, the coated substrates were sterilized with aqueous EtOH (70%) rinsed with sterile 
Dulbecco's phosphate-buffered saline (DPBS without calcium and magnesium, Sigma-Aldrich, 
Taufkirchen, Germany), and dried in a cell culture hood. Next, the substrates were placed in a sterile 
24-well plate (Sarstedt, Nümbrecht, Germany) and 500 μL DMEM containing osteoblasts (5 x 104 cells
per ml) was added to the substrates. The 24-well plate containing osteoblasts and substrates was
placed in an incubator (Heraeus Holding GmbH, Hanau, Germany) at 37 °C and 5% CO2. After overnight
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incubation, the cell culture medium was disposed and substrates were washed with sterile DPBS three 
times carefully. For the cells’ fixation, the cells were incubated with glutaraldehyde solution (2.5%) at 
room temperature overnight. The cells were gradually dehydrated by submerging the materials with 
cells in EtOH/H2O mixtures of v/v= 50/50, 70/30, and 100/0, for 10 min per mixture. Finally, the 
substrates were dried in hexamethyldizilane (Sigma-Aldrich, Taufkirchen, Germany) for 10 minutes at 
room temperature. The osteoblast cell attachment to the materials was investigated using the field 
emission scanning electron microscope (FE-SEM, Hitachi SU8030, Japan) at an accelerating voltage (Vac) 
of 20 kV, a current of 20 μA, and a working distance of 8.5 inch. Prior to the SEM experiments, all 
materials were sputtered with a 5-nm conductive gold layer using a compact coating unit CCU-010 by 
SafematicTM GmbH (Bad Ragaz, Switzerland). 
Release kinetics: The coated materials were incubated with pro-dapto of 0.5 μg/ml diluted in PBS for 
24 h. Next, the supernatant was removed and the materials were incubated in PBS for 3 h, 24 h, 4 days, 
7 days and 1 month. The PBS supernatant fractions were collected at each time point and a fresh buffer 
was added. Next the collected fractions were analyzed by HPLC. All kinetics samples were performed 
in triplicates.  
Measurement of the water contact angle: For the contact angle measurement, the dataphysics contact 
angle system OCA (Data Physics Instruments, Germany) was employed with the SCA202 software 
????????????????????? ???????????????????????????????????????????????????????????????????? ????????
at room temperature using a sessile drop method. Each surface was measured in at least 3 times with 
independent measurements on different locations of the material’s surfaces. The Milli-Q water drop 
volume was 2 μl, after the equilibration for 20 seconds the measurement of the contact angle was 
done.  
Coating stability: To test the coating stability, the coated samples were incubated for 1 month in 1% 
SDS. Followed by the XPS measurement. X-ray photoelectron spectroscopy (XPS) spectra were 
?????????????????????????? ????? ????????????????????????? ?????? ????????????????????-ray source 
using an analyzer pass energy of 80 eV for survey spectra and 20 eV for the core level spectra. The 
electron emission angle was 60° and the source-to-analyzer angle was 60°. The binding energy scale of 
the instrument was calibrated following a Kratos Analytical procedure, which used ISO 15472 binding 
energy data. Spectra were recorded by setting the instrument to the hybrid lens mode and the slot 
mode providing approximately a 300 x 700 μm2 analysis area using charge neutralization. All XPS 
spectra were processed with the UNIFIT program (version 2017). A Gaussian/Lorentzian sum function 
peak shape model GL (30) was used in combination with a Shirley background. If not otherwise 
denoted, the L-G mixing for component peaks in all spectra were constrained to be identical. Peak 
fitting of C 1s spectra was performed by fitting of all peaks to remove residual structures. After peak 
??????? ?????? ? ??????????????????????? ????????????????????????????????????????? –C bond C 1s component 
at a binding energy of 285.0 eV.  
Coating thickness: In order to determine the thickness of the MI-dPG-PEG-Tz coating, the titanium 
materials were masked according to technique described in literature.[35] Briefly, poly(D,L,-lactide) 
(PDLL) was dissolved in acetone (10%, w/v), and 25 μl of the solution was pipetted on the surface of 
the material, but covering only a part of the surface. The materials with the polymer were dried at 50 
°C for 1 h. Next, the substrates were coated according to the MI-dPG-PEG-Tz coating procedure. Next 
the PDLL was removed using tweezers, which resulted in a clear step in the coating and which allowed 
us to identify the thickness of the coating.  The vertical substrate holder (Figure 13) was used in order 
to enable the measurement of the thickness of the coating. The measurement was done using field 
emission scanning electron microscope (FE-SEM, Hitachi SU8030, Japan) at an accelerating voltage (Vac) 
of 20 kV, a current of 20 μA. 
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Figure 13. Vertical substrate holder enables the measurement of the coating thickness on the titanium 
material. 
Click Reaction: The click reaction between tetrazine-coated titanium materials and TCO-prodrug 
daptomycin. Click reaction between tetrazine-coated titanium materials and TCO on daptomycin was 
performed similarly to described already in our previous publication.[28] Briefly, tetrazine-coated 
titanium materials were placed in a freshly prepared mixture of Müller-Hinton cation adjusted medium 
(adjusted to final 50-55 mg Calcium/L) and pro-dapto with different concentrations (0.7 – 12 μM) for 
1 h at RT. Next MRSA was added and the reaction system was incubated overnight at 37 °C. Next day 
the microbiology analysis was performed.  
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Supporting Information is available from the _ or from the author. 
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Figure S1. 1H NMR spectrum of MI-dPG. 
Figure S2. MI-dPG structure.  
1H NMR (500 MHz; CD3OD): ?= 6.68-6.53 (1, 2, m, aromatic protons); 4.21-3.02 (6, 7, 8, 9, 13, m, dPG-
backbone); 2.75-2.52 (3, 4, m, DHHA aliphatic protons). 
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Figure S 3. Minimum inhibitory concentration for planktonic MRSA versus daptomycin for samples 
where no materials was present (w) and samples, which were previously incubated with MI-dPG-
PEG-tetrazine-coated material (MT). 
Figure S 4. Minimum biofilm prevention concentration (MBPC) of the daptomycin incubated either 
with not coated titanium (T) or MI-dPG-PEG-tetrazine-coated materials (MT).  
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2. Absorbance results: Fmoc deprotection by 20% piperidine.
The Fmoc deprotection was controlled by measuring the absorbance at 301 nm[1] of the
dibenzofulvene-piperidine adduct formation. Coated materials were incubated for 30 min with 20%
piperidine/DMF solution and the absorbance of the supernatant was measured. Results shown in
Table S1.
Sample Absorbance results at 301 nm 
Dibenzofulvene-piperidine adduct 1.56 ± SD 0.08 
Piperidine/DMF solution 0.27 ± SD 0.03 
Table S1. Absorbance results from the dibenzofulvene-piperidine adduct. 
The results show the increase in absorbance for dibenzofulvene-piperidine adduct, which 
suggested the Fmoc’s release from the surface. Incubation longer than 30 minutes did not 
increase the absorbance values. This indicated that the time 30 min was enough to deprotect Fmoc 
from the coated material’s surface.  
Reference 
1. Eissler S., Kley M., Bachle D., Loidl G., Meier T., Samson D., Journal of peptide science: an
official publication of the European Peptide Society, 2017, 23, 757.
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Amphotericin B is used for local delivery from polymethylmethacrylate to treat fungal prosthetic joint 
infections. The optimal amphotericin B formulation and the influence of different poragens in the bone 
cements are unknown. To investigate the necessary amount of amphotericin B in the bone cement to 
prevent Candida biofilm several amphotericin B formulations were studied: non-liposomal and liposomal 
with or without poragen gentamicin. For the non-liposomal formulation, standard bile salt, the sodium 
deoxycholate, was used and additionally N-methyl-D-glucamine/palmitate was applied. The activity of 
the released amphotericin B was tested against C. albicans, C. glabrata, C. parapsilosis and C. krusei 
biofilms with application of the isothermal calorimeter and standard microbiological methods. 
Compressive strength was measured before and after antifungal elution from the cements. There is less 
aggregated N-methyl-D-glucamine/palmitate amphotericin B released but its antifungal activity is 
equivalent with the deoxycholate amphotericin B. The minimum quantity of antifungal preventing the  
Candida biofilm formation is 12.5 mg in gram of polymer powder for both non-liposomal formulations. 
The addition of gentamicin reduced the release of sodium deoxycholate amphotericin B. Gentamicin 
can be added to N-methyl-D-glucamine/palmitate amphotericin B in order to boost the antifungal 
release. When using liposomal amphotericin B more drug is released. All amphotericin B formulations 
were active against Candida biofilms. Although compressive strength slightly decreased, the obtained 
values were above the level of strength recommended for the implant fixation. The finding of this work 
might be beneficial for the treatment of the prosthetic joint infections caused by Candida spp.   
Key words: amphotericin B-loaded bone cement, fungal prosthetic joint infection, bone cement spacer, 




Microorganisms form biofilms on the implant surfaces, which may cause persistence of infection [1, 2]. 
A combined surgical and antimicrobial treatment is required to efficiently eradicate implant-associated 
infections [3]. Periprosthetic joint infections may be caused by a wide range of microorganisms, including 
fungi [2, 4-6]. Among all periprosthetic joint infection, fungi are isolated in about 1 - 3%, predominantly 
yeasts [7-9]. Among Candida species, C. albicans has been reported to be the most prevalent pathogen, 
followed by C. parapsilosis, C. tropicalis and C. glabrata [7].  
Implant-associated infections caused by Candida represent a serious and complex complication [10], 
which is further challenged due to toxicity and limited activity of antifungals against biofilms [7, 9, 11]. In 
addition, no uniform guidelines for the management of fungal PJI exist and most authors suggest two-
stage or three-stage prosthesis exchange, combined with long-term systemic antifungal therapy with 
polyenes, echinocandins or azoles [3, 7, 12, 13]. Amphotericin B (AmB), one of the most active 
antifungals [14] is commercially available in two formulations. Amphotericin B deoxycholate (D-AmB) 
was initially used for the treatment of invasive fungal infections [15-17]. However, the poor water 
solubility and the high frequency of adverse effects after intravenous administration, such as infusion 
toxicity and nephrotoxicity, reduced its clinical use [18, 19]. The liposomal formulation has been 
developed in which amphotericin B is incorporated between lipids that compose of phospholipids and 
cholesterol [20]. Lipid formulations showed less nephrotoxicity [14] better tolerance and they replaced 
D-AmB in many institutions [19, 21].
Little data is available regarding the local use of antifungals in polymethylmethacrylate (PMMA) bone 
cement in the treatment of PJI, used either as temporary spacer or permanent fixation of the prosthesis 
[4, 6]. The thermal stability of AmB at temperature even greater than 70°C makes it an ideal candidate 
for inclusion into PMMA cement spacers [22]. In contrast, a commonly used echinocandin, caspofungin, 
shows limited thermal stability [23]. Due to low number of cases, the use of AmB-impregnated cement 
spacer has not been systematically investigated and its clinical efficacy remains controversial [9, 24]. 
Discordant results were obtained in in vitro and pilot clinical studies [25-27]. The analysis based on 
spectrophotometric measurement has shown a poor elution of non-liposomal AmB from bone cement, 
which is perhaps due to its covalent crosslinks in the PMMA matrix that increases the mechanical 
strength of the cement [22]. The liposomal formulation of AmB, although showing enhanced release of 
the drug, remains concerns regarding mechanical stability of the bone cements due to the high porosity 
resulted after polymerizing such materials [15].  
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The AmB structure composes of long, highly reactive unsaturated backbone, especially to the free 
radicals. The polymerization of the bone cements by the monomer can lead to the reaction of monomer 
with the double bond in the AmB. Therefore, the formed bond between the AmB and polymer chains 
lead to crosslinking of the antifungal within the cement matrix and the AmB cannot be released. This 
influences also the mechanical properties of such material by increasing the mechanical strength, a 
phenomenon known in polymer networks [22, 28]. 
Other studies showed that adding a poragen agent to PMMA improves the release of the antimicrobials, 
although it might decrease the strength of the cement [26, 29]. The amino-functional solubilizing agents 
such as polysaccharides, polyols, polyether and carboxylic acids, fatty acids encapsulate the antifungal 
agent and enhance the AmB release from PMMA bone cements [30]. In addition, the latter might help 
to disperse antifungal more homogenously and no solvent is needed for the emulsification of the drug 
and solubilizing agent. Thus, this might safe both material and time [30].  
As sodium-deoxycholate of AmB shows poor water solubility and infusion toxicity and nephrotoxicity [18, 
19] and liposomal amphotericin B involves incorporation into the bone cement large amount of liposomal
powder, which can negatively affect the mechanical stability of PMMA bone cements, we have 
investigated an alternative AmB formulation composes of amine sugar N-methyl-D-glucamine / palmitic 
acid (M-AmB). To our knowledge, no data was published for M-AmB release from bone cements so far. 
In this study we have investigated the release and activity of two standard AmB formulation from the 
bone cement and compared it with the M-AmB formulation. The objectives of this investigation were as 
follows: to determine which AmB formulation releases more active antifungal from the bone cement, to 
determine the AmB activity after the release from PMMA against Candida spp., to find AmB 
concentration which prevent formation of Candida biofilms and whether this concentration has a 
negative impact on the mechanical properties of bone. In addition, we have examined the same 
properties after addition of a poragen gentamicin to the cement.   
MATERIAL AND METHODS 
Candida strains and inoculum size. C. albicans (ATCC 90028), C. glabrata (DSY 562), C. krusei 
(ATCC 6258) and C. parapsilosis (ATCC 22019) were used. The strains were plated on Sabouraud 
dextrose agar (SAB) and incubated for 24 h at 37°C. The 1-4 x 105 CFU/ml inoculum was prepared 
using McFarland standard and the exact inoculum was determined by quantitative cultures.  
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PMMA cement cylinders and amphotericin B formulations. Cylinders (Ø 6 mm x 15 mm) were 
manufactured by Heraeus Medical (Wehrheim, Germany). Briefly, PMMA bone cements were prepared 
under chemical hood at room temperature. The available on the market original packages of Palacos 
R® and Palacos R+G® (industrially premixed with 0.5 g gentamicin) cements were used. The non-
liposomal AmB and liposomal AmB (AmBisome) were used as a powder. For the non-liposomal 
amphotericin B following amounts were used: 0.125, 0.25, 0.5, 0.75, 1g for 40 g of methyl methacrylate 
powder, with the addition of either sodium deoxycholate: 0.1, 0.21, 0.41, 0.61, 0.82g respectively or N-
methyl-D-glucamine/palmitate: 0.12, 0.25, 0.5, 0.75, 1g, with 18.8 g of monomer liquid (N,N-Dimethyl-
p-toluidin). For liposomal amphotericin B, 0.1, 0.2, 0.4, 0.83 and 1.66 g AmBisome was used in 10 g of 
polymer powder with 4.7 g of monomer liquid. PMMA cement powder, the antifungal and monomer liquid 
were blended properly together by hand. Next, the cement mixture was transformed to a metal mold 
with the wholes of Ø 6 mm x 15 mm. The cement cylinders dried at room temperature for 30min under 
a constant load of 1.3 tone. The prepared PMMA bone cement cylinders had a surface size of 0,3 cm2. 
The conventional non-liposomal AmB formulation: sodium-deoxycholate AmB (D-AmB) was compared 
with an alternative non-liposomal formulation N-methyl-D-glucamine/palmitate (M).  We have chosen N-
methyl-D-glucamine/palmitate as it has been shown that PMMA bone cement which contain 
amphotericin B encapsulated fully or partly by a mixture with 1-methylamino-1-deoxy sugar alcohol and 
at least one fatty acid increased the water solubility of the antifungal and released effective amounts of 
AmB into the aqueous solutions [30].  
The concentrations of different AmB-loaded PMMA cylinders evaluated in this study are summarized in 
Table 1.   
Table 1. Amphotericin B concentrations used in this study. 
Antifungal mg drug / cylinder 
Amphotericin B (mg)/ g 
polymer powder 
Liposomal 
amphotericin (mg)/ g 
polymer powder 
Amphotericin B  











Liposomal amphotericin B 
53 mg liposomal powder 
(2 mg AmB) 
28 mg liposomal powder 
(1 mg AmB) 
14 mg liposomal powder 







7 mg liposomal powder 
(0.3 mg AmB) 1 21
4 mg liposomal powder 
(0.1 mg AmB) 
0.4 10
We have used standard 0.5 g gentamicin/ 40 g polymer powder [29, 30]. As a control, cylinders without 
AmB were used. Following controls were used: PMMA without drug, PMMA without drug but with salts: 
sodium doexycholate or N-methyl-D-glucamine/palmitate, PMMA with gentamicin and salts.  
Biofilm formation. The biofilm was formed on PMMA cement cylinders as previously described [31, 
32]. Briefly, the PMMA cement cylinders were added to 2.7 ml advanced RPMI-1640 medium (Life 
Technologies corporation, NY, USA) and inoculated with 300 μl of diluted yeast stock solution (final 
inoculum size 1x 105 CFU/ml). Then, samples were incubated at 37°C for 24 h in static condition.  
Quantification of adherent yeast cells by sonication. After the overnight incubation, the PMMA 
cylinders were transferred to new tube and washed three times with 0.9% saline. Samples were then 
vortexed for 30 seconds, sonicated at 40 kHz for 1 minute (BactoSonic, Bandelin electronic, Berlin, 
Germany) and vortexed again for 30 seconds [2]. The resulting sonication fluid was plated on the 
Sabouraud dextrose agar and incubated at 37°C for 24 hours for colony counting. The minimum biofilm 
prevention concentration (MBPC) was defined as the lower AmB concentration which determined no 
Candida colonies on agar plates. After determination of the MBPC, the additional experiment was 
performed. The PMMA bone cements showing MBPC were incubated with C. albicans, the most 
common PJI Candida spp. pathogen, for a period of 2 weeks at 37°C in static conditions.   
Microcalorimetric assessment of adherent Candida remaining on the material after sonication. 
To evaluate the viable fungi remaining on the material, cement cylinders were placed after sonication in 
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calorimetric disposable 4 ml-glass ampoules (Waters GmbH, Eschborn, Germany) pre-filled with 3 ml 
of RPMI. The metabolism-related heat production was measured at 37°C for 24 h in an isothermal 
microcalorimeter (TAM III; TA Instruments, New Castle, DE, USA), according the same procedures 
described in the previous studies [33, 34]. This method is a very sensitive technique to assess 
microorganism’s growth. The heat production of the metabolic active pathogens is measured over a 
period of time [34]. The amount of fungi on the PMMA cements can be quantitatively assessed in real 
time. The assessment of the fungi can be done by analyzing the heat flow curve, the delay of heat 
production or reduction of peak heat flow. No heat production indicates no proliferating microorganisms. 
The results were plotted as heat flow [μW] over time. Experiments were performed in triplicates. As a 
control for the baseline, samples with no Candida spp. were used. The calorimeter manufacturer’s 
software (TAM Assistant; TA Instruments) was used for the data analysis.  
Quantification of released amphotericin B. Each PMMA cylinder loaded with AmB was incubated in  
3 ml PBS, at 37°C in order to evaluate the drug release. The eluate was exchange after 24 hours and 
48 hours. The elution samples were collected, after 24h, 48h and 7 days. Each of them was measured 
separately using spectrophotometer at the absorbance at 328 nm wavelength (Epoch 
Spectrophotometer, BioTek, Bad Friedrichshall, Germany). In aqueous condition, the non-liposomal 
AmB is aggregated and the absorption spectrum is composed of one broad peak at 328 nm [35]. For 
liposomal-AmB the absorbance was measured at 412 nm as indicated by Vandermeulen et al. [35]. The 
standard curves were prepared from AmB samples of known concentration for all tested formulations. 
To determine the concentration of AmB the interpolation of the standard curves was done. The release 
of liposomal and non-liposomal AmB was analyzed using repeated-measures ANOVA. The statistical 
analysis was performed using Prism 7.03 (GraphPad Software, La Jolla, CA, USA). The measurement 
was performed in triplicates. 
Compressive strength testing. The measurement was done before and after AmB elution. This was 
a cumulative release over 7 days measured at 24 h, 48 h and on day 7. Experiments were performed 
in triplicates. For the measurement, the cylinders that showed previously MBPC values were taken as 
these samples show a potential perspective for the further in vivo studies. Each PMMA cylinder was 
incubated in 3 ml PBS. The elution buffer was exchanged after 24 and 48 hours, respectively. The 
cement cylinders were loaded to failure in axial compression according the ISO 5833 using the material 
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testing machine (Zwick/Roell Z010, Ulm, Germany). Compression force and displacement were 
recorded with a software (TestXpert II, Zwick, Ulm, Germany) at an acquisition rate of 100 Hz. The 
differences in the compressive strength were analyzed using a Mann-Whitney test. 
Electron microscope PMMA material surface analysis 
To evaluate the morphology of the surface area of PMMA samples, samples that showed MBEC were 
selected. The analysis of the surface was done using the scanning electron microscope and the analysis 
of the lateral surface was performed. 
Density and porosity measurement of the PMMA bone cement samples  
To assess the porosity of PMMA bone cements μCT was performed. The height and the diameter of 
every single sample was measured using a caliper with LCD digital output (Digit-Cal 5S; Tesa, 
Switzerland) and following that samples were weighed using a microbalance (ME 36S; Sartorius, 
Germany) in order to calculate the samples densities. 
The Specimens were then placed in a Viva40 μCT (Scanco Medical AG, Bruettisellen, Switzerland) and 
a consistent ROI (212 slices) were scanned at a voltage of 45 kVp (kilovolt peak), a current of 176 μA. 
The resulting images were semi-automatic segmented and analyzed in terms of radiodensity (HU). 
To porosity was quantified from the micro-CT data and calculated as the ratio between the volume of 
residual material and the total volume of the materials, whereby a threshold of 1487 HU was used to 
distinguish background cavities from material. Separation is the voidspace (spacing of background). 
RESULTS AND DISCUSSION 
AmB is an effective antifungal molecule used as drug of choice for the management of fungal infections. 
AmB has a poor water solubility, therefore is commonly formulated as a sodium deoxycholate [15].The 
activity and the amount of the drug released from PMMA has been a subject of much debate in the 
literature [15, 22, 26, 27]. Due to this fact, in the following study, an innovative approach was applied. 
The solubilizing agent N-methyl-D glucamine/palmitate for the AmB was used to determine its influence 
on the release of the drug. The local biofilm activity of liposomal and non-liposomal AmB, eluted from 
PMMA bone cement was studied.  
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 Evaluation of the minimum biofilm prevention concentration of different AmB formulations 
released by PMMA cylinders.   
PMMA cement represents an abiotic surface to which microorganisms can attach and form a biofilm on 
it. The ability of C. albicans, C. glabrata, C. parapsilosis and C. krusei to form biofilm on bone cement 
cylinders with or without AmB was evaluated by a colony counting of sonication fluids, followed by an 
additional analysis using isothermal microcalorimetry.   
The absorbance analysis of the released AmB cannot provide information regarding the number of 
active molecules. However, our biofilm quantification studies showed antifungal activity of the released 
drugs. Similarly to the reports and studies showed by Mara et al.[27], who also used Palacos bone 
cements, showed clinically relevant release of AmB from acrylic bone cements in drain fluids.  Wu et al. 
[24] reported a successful resection arthroplasty with AmB cement spacer against Candida albicans
infection. In the case report done by Deelstra et al. [36] also was observed a significant release of AmB 
and voriconazole from bone cement for at least 72 hours, which finally resulted in the cure of 
Candida albicans infection in the treated patient. The MBPC of different antifungals against tested 
Candida species are reported in Table 2.   
Table 2. The minimum amount of non-liposomal and liposomal amphotericin B needed to prevent 
the Candida spp. biofilm formation on the PMMA cylinders.   
Antifungal formulation Sonication fluid 
MBPC [mg drug/ g polymer powder] 
C. albicans C. glabrata C. parapsilosis C. krusei
D 6 6 12.5 12.5
D + G 19 12.5 12.5 12.5 
M 12.5 12.5 12.5 12.5
M + G 6 6 6 12.5 
Liposomal 
amphotericin B  









MBPC: minimum biofilm prevention concentration, D: sodium deoxycholate, M: N-methyl-D-glucamine/palmitate, 
G: gentamicin [0.5 g/ 40 g polymer powder].  
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The MBPC results show that to cover all tested Candida spp. D-AmB and M-AmB provide the same 
biofilm prevention activity 12.5 mg / g polymer powder. The addition of gentamicin to M-AmB decreased 
the MBPC from 12.5 mg / g PP to 6 mg / g PP for tested Candida species, except for C. krusei.   
D-AmB cement with gentamicin as poragen increased MBPC from 12 mg to 19 mg AmB / g polymer
powder. In contrast to the results showed by Kweon, the addition of poragen in our study did not improve 
significantly the release of AmB. Using the same cylinder size, Kweon showed that after 15 days of time 
there was 12.76 μg AmB released per cylinder when poragen was used and 1.74 μg / cylinder when no 
poragen was present [26]. We have observed that addition of the poragen decreased the MBPC only 
when M-AmB was used. Kweon [26] used 50 times more poragen than AmB. We have tested the 
following, much lower, ratios: 1 AmB: 1 poragen, 2 AmB: 1 poragen, 1.5 AmB: 1 poragen, 0.5 AmB: 1 
poragen and 0.25 AmB: 1 poragen. Using less poragen might explain why in our study the addition of 
poragen did not enhance the release of the AmB. We have used 0.5 g gentamicin / 40 g polymer powder, 
which is a standard amount used in the commercial cements within the range of 1.25-2.5% gentamicin 
of the powder component in PMMA cements [37, 38]. More poragen might improve the release rate of 
the drug but it might also diminish the mechanical properties of the cements [37].  
Compared to non-liposomal-AmB formulations, the MBPC of liposomal-AmB was lower for all the 
Candida spp. ranging from 0.4 to 2 mg of pure AmB /g polymer powder (Table 1). One has to notice 
that to reach 0.4÷2 mg of AmB / g PP, there is 4÷53 mg of L-AmB / g polymer powder needed. These 
data support the hypothesis that all released non-liposomal and liposomal AmB showed anti-Candida 
activity. Figure 2 A-D depicts Candida spp., showing that all four species incubated for 24 h formed 
biofilm on PMMA, both with and without AmB (i.e. growth controls).   
The results from the 2 weeks of incubation of PMMA cements with C. albicans showed that there is no 
growth of fungi for samples with M-AmB, M/G-AmB, D-AmB, D/G-AmB. It indicates that the non-
liposomal AmB amounts which showed MBPC values, turned to be enough to protect materials from C. 
albicans colonization for a prolonged incubation period. However, Candida growth was observed for 
samples with L-AmB (2 mg drug / g PP). The amount of C. albicans cells found after 2 weeks of 
incubation was 3.8x103 CFU/ml. It indicates that for the liposomal samples in order to protect the 




Figure 2 A-D. Heat flow produced by A: C. albicans, B: C. glabrata, C: C. parapsilosis, D: C. krusei remained on 
the PMMA cylinders with non-liposomal amphotericin B after sonication. The control arms are the samples 
named GC (growth controls) without antifungals but with solubilizing agents and with or without poragen.  GC: 
growth control without antifungal drug, PP: polymer powder, G: gentamicin, D: sodium deoxycholate, D/G: 
sodium deoxycholate with gentamicin, M: N-methyl-D-glucamine/palmitate and M/G: N-methyl-
Dglucamine/palmitate with gentamicin. Negative controls (PMMA materials without Candida spp.) did not show 
heat production. The concentration given in mg of the drug in gram of the polymer powder.  
In order to evaluate the presence of viable Candida cells remaining on the cylinders after the sonication 
procedure, isothermal microcalorimetry analysis of all the materials was performed. The sonicated 
materials were placed in the fungi growing medium and transferred into the isothermal microcalorimeter 
for the analysis. The presence of the Candida cells on the materials was associated with producing the 
heat curves, as the proliferating cells produce heat. As shown in Figure 3 A-D, no heat production was 
detected during 24 hours for the tested samples, indicating that all the biofilm-embedded cells were 
removed from the cylinders by sonication.   
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Figure 3 A-D.  Heat flow produced by A: C.albicans, B: C.glabrata, C: C.parapsilosis, D: C.krusei remained on the 
PMMA cylinders with liposomal amphotericin B after sonication.  
By contrast, the heat production was observed in the samples of cylinders without the antifungal, 
suggesting that a strong biofilm was formed on PMMA in absence of AmB, as the sonication procedure 
was not able to completely dislodge it. Moreover, comparing the elution results with sonication fluid 
results we showed that AmB was released in active form causing Candida inhibition growth. The heat 
flow produced by the control samples from C. krusei might indicate that this strain do not produce so 
much biofilm as the other Candida species tested in this work.  
Quantification of different amphotericin B formulations, with and without gentamicin, released 
by PMMA cylinders. The cumulative drug amounts released from PMMA cylinders, after 7 days 
incubation in PBS, are reported in Figure 1A and 1B, respectively for non-liposomal and liposomal AmB. 
Besides, the effect of gentamicin addition in the cement on antifungal release was investigated as well 
(Figure 1A).   
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Figure 1. A) The cumulative release at day 7 for the non-liposomal amphotericin B at 328 nm in four different 
formulations: non L-AmB: non liposomal amphotericin B, D- AmB: sodium deoxycholate amphotericin B, D- AmB/ 
G: sodium deoxycholate amphotericin B with gentamicin, M-AmB: N-methyl-D-glucamine palmitate amphotericin B 
and M-AmB/ G: N-methyl-D-glucamine palmitate with gentamicin. The drug amounts are given per PMMA cylinder. 
B) The cumulative release at day 7 for the liposomal amphotericin B at 412 nm based on formulation and dose. L-
AmB: liposomal amphotericin B. The drug amounts given per PMMA cylinder. The whiskers represent standard
error measurement.
The presence of sodium deoxycholate released more non-liposomal-AmB in comparison to N-methyl-
D-glucamine/palmitate AmB, even though this difference was not statistically significant. Although more
D-AmB (range 209 ÷ 41 μg) than M-AmB (151 ÷ 6 μg) was released, the D-AmB antifungal activity was
inferior to the M-AmB activity. For both AmB there was 12.5 mg drug / g polymer powder needed to 
reach minimum biofilm prevention concentration (MBPC) for all tested Candida spp. These findings 
might suggest that not all the released D-AmB was biologically active. Although, less amount of released 
M-AmB was observed, its activity against Candida was analogous to that obtained with higher amount
of D-AmB released. A possible explanation might be related to the solubility of these two bile salts. 
Sodium deoxycholate water solubility is lower (0.02 g / ml at 20°C) [39], in comparison to N-methyl-D 
glucamine solubility in water (up to 1 g / ml at 20°C) [40]. This might result in a different aggregation 
state of AmB which is visible by the cumulative data. There was more D-AmB (absorbance at 328 nm 
[35]) than M-AmB in aggregate state. We hypothesize that M-AmB has a different particle size within 




AmB and its aggregation state [37]. The less aggregated state of AmB is favorable as there is weaker 
interaction of AmB with mammalian cell membranes [41].  
In contrast to Chang et al. who reported the release of 86 μg / ml for AmB with xylitol as an inert filler 
and 52 μg / ml for powder AmB, after 10 days from initial 2 g AmB load 40 g polymer powder, our study 
showed 209 μg / ml D-AmB and 154 μg / ml M-AmB release after 7 days from the cylinders with 1 g 
AmB / 40 g polymer powder. Interestingly, Chang et al. used cylinders of the higher surface size ~ 1,3 
cm2, than used in our study 0,3 cm2.  
These findings do not support the theory that the larger the surface the more drug is available on it and 
hence more drug is released [37]. However, they lead us to speculate that there are two factors which 
might explain the difference in the amount of AmB in eluates. Firstly, Chang used a bone cement by a 
different manufacturer. These bone cements have various copolymers and additives when compared to 
the cement used in our studies [37]. Secondly, we believe that the solubilizing agents used in our study 
for AmB formulations are of major importance for the release of the drug.  
The AmB formulation seems to be crucial, as already reported by Chang the drug, although released, 
shows no inhibition zone for Candida albicans for the powder AmB and AmB/xylitol. In our study, all 
AmB formulations, after release, maintained antifungal activity against all tested Candida spp.   
Our results showed lower elution of D-AmB when gentamicin was used. Its addition reduced the release 
of D-AmB from 209 ÷ 41 μg to 175 ÷ 21 μg. These results show that the addition of gentamicin to the 
cement with D-AmB did not improve the release rate of this antifungal, on the contrary, there was less 
D-AmB released. It was also reflected in the MBPC results. Interestingly, Goss et al. [22] reported that
the addition of tobramycin to D-AmB cements reduced the total elution rate of tobramycin. This could 
also have happened with the gentamicin used with D-AmB. These two antibiotics belong to the same 
group of aminoglycosides. Both are well soluble in water, hydrophilic drugs [42, 43]. According to the 
above mentioned, we hypothesize that the hydrophobic properties of the poragen and highly 
hydrophobic AmB [44] might interact with each other and, in consequence, influence the release. This 
might result in the diminished elution rate of both antibiotic and antifungal.  
Adding a gentamicin to M-AmB loads of 0.75 ÷ 0,125 g / 40g polymer powder showed a beneficial effect 
by improving the AmB elution amounts. The release amounts were higher 103 ÷ 14 μg as compared to 
100 ÷ 6 μg where no poragen was used. These results imply that M-AmB interaction with gentamicin is 
different from D-AmB. Following this line of reasoning, it might be assumed that hydrophobic vs. 
hydrophilic interaction between cement ingredients contribute to the difference in the release of the 
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molecules, as well as the particle size of active substance and their distribution among the cement. 
Potentially, these findings show that M-AmB might be a better choice if use non-liposomal AmB for bone 
cements. M-AmB releases less aggregated AmB at the same time having equal antifungal activity to 
the D-AmB. We report that non-liposomal D-AmB and M-AmB have been released from the bone 
cement without any help of a poragen. Our data are in line with those of Houdek [45] and Cunningham 
[15] studies. Houdek et al. [45] reported a detectable amount of D-AmB in the eluate, which is consistent
with our study. However, we cannot compare the amount of released D-AmB with our findings as the w 
/ w of D-AmB used in Houdek study was 7.5% whereas our maximum D-AmB w / w was 2.5%. 
Cunningham [15] reported the release of 23 μg D-AmB after 7 days from 800 mg initial amount in the 
cement. Our 750 mg D-AmB load in the cement released 154 μg of the drug after 7 days. Closer 
inspection of this study reveals that the cylinder size used in our study is slightly bigger 0.34 cm2 than 
the one used by Cunningham 0.28 cm2. Moreover, the amounts of elution buffer differ from 3 ml in our 
study to 5 ml in Cunningham study. We believe that these two factors together with different cements 
used in our study and their powder components [37], might provide an explanation for the difference in 
the released amounts of D-AmB.   
We report the release of D-AmB from each tested cylinder, regardless of either absence or presence of 
poragen. These findings do not support the data showed by Goss et al. [22]. He reported that after 168 
h of elution, there was no D-AmB detected in the eluate. Within the sensitivity limit 1 μg/L, no drug could 
be measured. In contrast to our study, Goss et al. used cements with different composition of the powder 
components, which might have an impact on the release. Apparent discrepancies might be due to the 
amount of elution buffer used by Goss et al. that was 250 ml. In our study, there was only 3ml used. In 
other words, the concentration of released D-AmB in our study was higher and hence the drug detection 
was possible. Another possible explanation is that the amount of D-AmB used in our study was higher 
than those used by Goss et al. This might be a reason why here more drug was released, accordingly 
more powder in the cement create more porous cements and the release is therefore facilitated. As 
shown in Figure 1B, a dose-dependent release of L-AmB was observed. After 7 days, a total release of 
109 μg, 15 μg, 5 μg, 2 μg and 1.6 μg L-AmB was observed from initial 2 mg, 1, 0.6, 0.3, 0.1 L-
AmB/cylinder, respectively (corresponds to 1.7, 0.8, 0.4, 0.2, 0.1 g L-AmB / 10 g polymer powder).   
Our results are comparable to those reported by Cunningham [15] where higher release was shown 
with L-AmB than with D-AmB and the release increased for greater load of AmB in the cement. As the 
94
16 
antimicrobial release rate from the bone cements depends on the roughness and porosity of the cement 
[37] we assume that the higher release observed for L-AmB is related to its formulation which has a
larger volume of powder. The L-AmB composes of AmB powder and liposomes powder. At the same 
time, it provides a larger porous structure of the cement. These results support the hypothesis that more 
powder of the active substance within the bone cement releases more drug [37]. As the complete 
release of AmB from the PMMA was not observed, we assumed that crosslinking between AmB and 
PMMA might occur and not all AmB can be released, as already reported by Nugent et al [29].  
Analysis of the cement cylinders strength.  
After 7-days elution of AmB, the compressive strength resulted slightly reduced in all the eluted cement 
samples, as shown in Figure 4.   
Figure 4. Compressive strength in MPa of the bone cements which showed the MBPC (amount of amphotericin B 
(AmB) in g/ 40 g polymer powder). Black bars are the compressive strengths for the materials before elution and 
grey represents the results after elution. D-AmB: sodium deoxycholate amphotericin B, D-AmB/ G: sodium 
deoxycholate amphotericin B with gentamicin, M-AmB: N-methyl-D-glucamine/palmitate amphotericin B, M-AmB/ 
G: N-methyl-D-glucamine/palmitate amphotericin B with gentamicin, L-AmB: liposomal amphotericin B   
The average compressive strength of non-eluted samples ranged between 114 MPa to 97 MPa, while 
after elution the values varied from 101 MPa to 89 MPa. However, none of the tested AmB formulations 
showed a statistically significant difference in the compressive strength after elution. The MBPC for the 
liposomal formulation caused a non-significant change in the compressive strength after elution.  
95
17 
In contrast to results reported by Cunningham et al., we report compressive strength of 94 MPa for 
liposomal bone cements after elution, which is above the recommended level by ISO 5833 (70 MPa) 
[15]. The difference might be in higher volumes of the elution buffer and different amount liposomal AmB 
used by Cunningham et al. For the non-liposomal deoxycholate formulation, our results were consistent 
with those obtained by Cunningham et al. [15] Goss et al. [22] and Kweon et al. [26] (compressive 
strength above 100 MPa). Nevertheless, contrary to our results, Kewon et al. observed significant 
decrease in compressive strength after elution when high-dose of poragen was used. The low-dose of 
poragen used in our study might be the explanation. We report no significant decrease in compressive 
strength when 12.5 mg gentamicin / g PP was added, as already reported by Goss et al. when 1g of 
tobramycin / batch was used as poragen [22].   
We have shown no significant change in compressive strength regardless the AmB formulation which 
are comparable findings with Chang et al. [46] Although compressive strength slightly decreased, the 
obtained values were above the strength recommended for the implant fixation. However, we 
hypothesize that in larger scale (patient treatment) the compressive strength of materials with L-AmB 
might decrease significantly.   
Electron microscope PMMA material surface analysis 
Figure S1. Shows the results from the SEM surface analysis of the samples that showed MBEC were 
selected. On each surface there are visible irregularities and scratches, which probably result from the 
polymerization process in metal molds. The sample with liposomal AmB (Figure S1, B) shows black 
spots which are the pores resulting of mixing large amounts of liposomal AmB powder with PMMA bone 
cement constituents. In this case the porosity visible on the surface is greater than in PMMA bone 
cement where D-AmB or M-AmB was used. The greater porosity of liposomal AMB PMMA bone cement 
surface, might explain why liposomal AmB in larger than D-AmB or M-AmB quantity is released to the 
liquid medium. Higher porosity allows better liquid penetration of the PMMA material. In the case of M-
AmB mixed with gentamicin, more pores are visible than without gentamicin. The addition of gentamicin, 
resulted in higher number of pores which is beneficial as the PMMA material penetration by a liquid. 
This may also explain why the addition of gentamicin has led to a lower MBEC for M-AmB. 
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PMMA bone cement density and porosity measurement 
The porosity results are summarized in Table S1 in the supplementary information. The smallest porosity 
was found in PMMA bone cement with M-AmB 0.0100, the largest porosity appeared in samples with 
liposomal AmB 0.0257 (Table S1). The difference between these two groups is significant. Higher 
porosity provides higher elution rate for the drug from PMMA bone cements [47, 48]. Therefore, an 
increase in porosity in the liposomal AmB PMMA may explain why from these materials more antifungal 
is released than if other AmB forms are used.  
The density measurement showed that there were no signified differences between the samples. The 
results are summarized in Table S2 in supporting information. The lowest density was recorded for M-
AmB PMMA 1.222 g/cm3 and the highest for PMMA bone cement with M+G-AmB 1.238 g/cm3. 
CONCLUSIONS 
The following study provides the data about the minimal amount of AmB that prevents Candida spp. 
biofilm growth on the PMMA, representing the standard PMMA quantity used in a clinical approach for 
antibiotic impregnated cement. Sonication and microcalorimetry experiments indicated that AmB 
released from bone cements prevented Candida biofilm formation in all cement forms. The addition of 
poragen gentamicin has an advantage when used with M-AmB, but there is no improvement when used 
with D-AmB.   
In conclusion, our study showed that AmB has been released from bone cement regardless of the AmB 
formulation. Each of the tested AmB amounts remain the antifungal activity after the release. N-methyl-
D-glucamine/palmitate AmB showed advantage over the conventional deoxycholate formulation which
potentially might be beneficial when choosing the AmB formulation for bone cement formulation. The 
release profile of AmB might depend on the composition of the powder components of the cements, 
particle size of the active substance and its hydrophobic and hydrophilic properties.   
We report that gentamicin poragen does not enhance the elution rate of D-AmB but improves the release 
of M-AmB. None of the tested cements showed a significant decrease in the compressive strength.  
There are further in vivo studies required in order to deeply study the antifungal properties of released 
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5. SUMMARY AND CONCLUSIONS
Implant-associated infections are devastating complications. The implant surface is very easy 
to be colonized by bacteria, which then form a biofilm. The biofilm on the implant surface is 
difficult to eradicate. Therefore, the prevention procedures for an implant surface are of crucial 
importance.2 Prevention of the implants begins with knowledge of the factors that cause the 
risk of infection, which can lead to the development of infection in different stages: pre-
operatively, intraoperatively, or postoperatively.237 The systemically injected antibiotic spreads 
through the entire body. As a result, the concentration, which arrives to the infection site is 
mainly sublethal, causes a persister cell formation.238 The insufficient dosage of such 
antimicrobials leads to unresolved infection because it often does not reach the infected site. 
Therefore, there is a critical need for a novel solution, either one, which allows the drug to 
reach the infection with high concentration and improve the biofilm penetration, or the one, 
which helps the implant surface hinder bacteria colonization.  
In this PhD work few strategies for biofilm-based infections were introduced: prodrug antibiotic 
local delivery based on biorthogonal chemistry, antimicrobial coating against S.aureus utilizing 
the inverse-electron demand Diels-Alder reaction and MI-dPG polymer, antifungal 
impregnated PMMA bone cements against Candida spp. biofilms and electro-responsive 
hydrogels with photosensitizer curcumin release against MRSA.  
In the first project it has been shown that the tetrazine-modified biomaterial, boost the activation 
of multiple doses of TCO-prodrugs in vitro and in vivo. These results indicate that therapeutic 
efficacy of antibiotics can facilitate the removal of bacterial infections, at the same time 
antibiotic side-effects can be reduced. Bio-orthogonal chemistry for prodrug antibiotic delivery 
has a wide range of applications and can be a potential candidate for the clinical usage in the 
treatment of implant-associated infections. In conclusion, the flexibility of placing the tetrazine-
alginate hydrogel as a target for the antibiotics in any desired location allows to use it for any 
type of implant-associated infection regardless the kind of implant material.  
In the second project the introduction of tetrazine to the MI-dPG coating was capable of 
daptomycin prodrug concentration and activation at the implant surface. The release of an 
active drug it into the implant surrounding enhanced the elimination of the MRSA bacteria. The 
results showed that MI-dPG-tetrazine coating does not require the incorporation of an antibiotic 
into the coating immediately. Such an implant coating allows for a drug modification already 
after the implant has been inserted into the patient's body.  The benefit is that the pathogen 
does not need to be known at the time of the implant insertion. As a future perspective it is 
expected that such coated implant can be loaded with several different antibiotics, which can 
be reloaded and released multiply times from the implant, by simply injecting the antibiotic 
intravenously without the need for further surgery.  
In the third project, the PMMA studies with different AmB formulations showed that all tested 
formulations are releasable from PMMA bone cements and remained active against Candida 
spp. Although the compressive strength was reduced for liposomal AmB, it was still within the 
ISO 5833 standard. The density remained at the same level for all tested formulation, whereby 
the porosity of the materials was greatest for liposomal AmB. The new N-methyl-D-
glucamine/palmitate AmB formula showed comparable efficacy to the AmB deoxycholate with 
an enhanced activity and release, when poragen was added. In conclusion, the results showed 
a potential use for N-methyl-D-glucamine/palmitate AmB for incorporation into the PMMA bone 
cement as an alternative to AmBs, which are currently available on the market.  
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In the fourth project the results from the electro-stimulated hydrogels showed that curcumin 
can be released from the such materials and the release kinetic can be modulated. The 
viability of the human fibroblast cells was higher than 94% and released curcumin showed 
90% growth inhibition of MRSA. In conclusion, it was demonstrated that curcumin loaded 
electro-responsive hydrogels can be applied for antimicrobial approaches.  
6. KURZZUSAMMENFASSUNG
Implantat-assoziierte Infektionen können zu verheerenden Komplikationen führen. Die 
Implantatoberfläche lässt sich sehr leicht von Bakterien besiedeln, die dann einen Biofilm 
bilden. Der Biofilm auf der Implantatoberfläche ist schwer zu beseitigen. Daher sind die 
Präventionsverfahren für eine Implantatoberfläche von entscheidender Bedeutung.2 Die 
Prävention der Infektion beginnt mit dem Wissen über die Infektionsverursachenden Faktoren, 
welche präoperative, intraoperative sowie postoperative Infekte verursachen können.237  
Systemisch injizierte Antibiotika haben zum Nachteil, dass sie sich im gesamten Körper 
verteilen und somit nur eine geringe Dosis der Anfangskonzentration am Infektionsort 
ankommt. Die unzureichende Dosierung solcher antimikrobieller Mittel führt zu einer 
ungelösten Infektion.238 Daher besteht ein dringender Bedarf an neuartigen Lösungen, 
entweder eine, die es dem Medikament ermöglicht, die Infektion mit hoher Konzentration zu 
erreichen und die Biofilmdurchdringung zu verbessern, oder eine andere, die dazu beitragen 
kann, die Implantatoberfläche vor einer Bakterienbesiedlung zu schützen. 
In dieser Doktorarbeit werden einige Strategien gegen biofilmbasierte Infektionen vorgestellt: 
lokale Prodrug Antibiotika Verabreichung basierend auf bioorthogonale Chemie, 
antimikrobielle Beschichtung gegen S. aureus unter Verwendung der Diels-Alder-Reaktion mit 
inversem Elektronenbedarf und MI-dPG-Polymer, antimykotisch imprägnierte PMMA-
Knochenzemente gegen Candida Biofilme und elektroreaktive Hydrogele mit photosensibler 
Curcumin Freisetzung gegen methicillinresistente S. aureus.  
Im ersten Projekt wurde gezeigt, dass das Tetrazin-modifizierte Biomaterial die Aktivierung 
mehrerer Dosen von TCO-prodrug in vitro und in vivo fördert. Diese Ergebnisse deuten darauf 
hin, dass die therapeutische Wirksamkeit von Antibiotika die Beseitigung bakterieller 
Infektionen erleichtern kann, während gleichzeitig die antibiotischen Nebenwirkungen 
reduziert werden können. Die bioorthogonale Chemie zur Verabreichung von Prodrug-
Antibiotika hat ein breites Anwendungsspektrum und kann ein potenzieller Kandidat für den 
klinischen Einsatz bei der Behandlung von Implantat-assoziierten Infektionen sein.  
Im zweiten Projekt war die Einführung von Tetrazin in die MI-dPG-Beschichtung in der Lage, 
die Prodrug-Konzentration und Aktivierung von Daptomycin an der Implantatoberfläche zu 
erreichen. Die Freisetzung eines aktiven Medikaments in der Implantat Umgebung erhöhte die 
Ausrottung der MRSA Bakterien. Die Ergebnisse zeigten, dass die MI-dPG-Tetrazin 
Beschichtung nicht sofort die Einarbeitung eines Antibiotikums in die Beschichtung erfordert. 
Eine solche Implantatbeschichtung ermöglicht eine Modifikation mit Antibiotika bereits nach 
dem Einsetzen des Implantats in den Körper des Patienten.  Der Vorteil ist, dass der Erreger 
zum Zeitpunkt der Implantat Insertion nicht bekannt sein muss. Als Zukunftsperspektive wird 
erwartet, dass ein derart beschichtetes Implantat mit mehreren verschiedenen Antibiotika 
beladen werden kann, die durch einfache intravenöse Injektion des Antibiotikums ohne weitere 
Operation mehrfach aus dem Implantat freigesetzt und wieder eingesetzt werden können.  
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Im dritten Projekt wurde gezeigt, dass alle getesteten Amphotericin B (AmB) Formulierungen 
aus PMMA-Knochenzementen freigesetzt wurden und ihre Aktivität gegenüber Candida spp. 
nicht verlieren. Die Druckfestigkeit wurde für das Liposomale AmB reduziert, lag aber immer 
im Rahmen der ISO 5833 Norm, die Dichte bleibt für alle getesteten Formulierungen gleich, 
die Porosität der Materialien war für das Liposomale AmB am größten. Die neue N-Methyl-D-
glucamin/Palmitat-AmB-Formel zeigte eine vergleichbare Wirksamkeit wie das AmB-
Desoxycholat, mit einer erhöhten Aktivität und Freisetzung bei Zugabe von einem Porogen. 
Zusammenfassend zeigten die Ergebnisse eine Wirksamkeit für N-Methyl-D-
glucamin/Palmitat AmB als Alternative zu den auf dem Markt erhältlichen AmBs, die in den 
PMMA-Knochenzement eingebaut werden können.  
Im vierten Projekt wurde festgestellt, dass Curcumin aus den elektrostimulierten Hydrogelen 
freigesetzt wurde und die Freisetzungskinetik moduliert werden kann. Die Lebensfähigkeit der 
menschlichen Fibroblastenzellen war höher als 94% und freigesetztes Curcumin zeigte 90% 
Wachstumshemmung von methicillin-resistentem S. aureus. Weiterhin wurde gezeigt, dass 
Curcumin beladene, elektroreaktive Hydrogele für antimikrobielle Ansätze eingesetzt werden 
können. 
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